Du benytter en nettleser vi ikke støtter. Se informasjon om nettlesere

17. Referanser

Aberle, D. R., Adams, A. M., Berg, C. D., Black, W. C., Clapp, J. D., Fagerstrom, R. M., . . . Team, N. L. S. T. R. (2011). Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med, 365(5), 395-409. doi:10.1056/NEJMoa1102873

Aberle, D. R., DeMello, S., Berg, C. D., Black, W. C., Brewer, B., Church, T. R., . . . Team, N. L. S. T. R. (2013). Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med, 369(10), 920-931. doi:10.1056/NEJMoa1208962

Agnelli, G., Becattini, C., Meyer, G., Muñoz, A., Huisman, M. V., Connors, J. M., . . . Investigators, C. (2020). Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med, 382(17), 1599-1607. doi:10.1056/NEJMoa1915103

Aguilar, E., Gainor, J., Kravets, S., Khosrowjerdi, S., Lydon, C., Adeni, A., . . . Awad, M. (2018). Outcomes in NSCLC Patients Treated with First-Line Pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 0-89% vs 90-100%. J Thorac Oncol, 13(10), S367-S368.

Al-Ibraheem, A., Hirmas, N., Fanti, S., Paez, D., Abuhijla, F., Al-Rimawi, D., . . . Mansour, A. (2021). Impact of (18)F-FDG PET/CT, CT and EBUS/TBNA on preoperative mediastinal nodal staging of NSCLC. BMC Med Imaging, 21(1), 49. doi:10.1186/s12880-021-00580-w

Al-Sahaf, M., & Lim, E. (2015). The association between surgical volume, survival and quality of care. J Thorac Dis, 7(Suppl 2), S152-155. doi:10.3978/j.issn.2072-1439.2015.04.08

Albain, K. S., Swann, R. S., Rusch, V. W., Turrisi, A. T., Shepherd, F. A., Smith, C., . . . Cox, J. D. (2009). Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet, 374(9687), 379-386. doi:10.1016/S0140-6736(09)60737-6

Aldea, M., Marinello, A., Duruisseaux, M., Zrafi, W., Conci, N., Massa, G., . . . Besse, B. (2023). RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion. J Thorac Oncol, 18(5), 576-586. doi:10.1016/j.jtho.2022.12.018

Ali, M. S., Trick, W., Mba, B. I., Mohananey, D., Sethi, J., & Musani, A. I. (2017). Radial endobronchial ultrasound for the diagnosis of peripheral pulmonary lesions: A systematic review and meta-analysis. Respirology, 22(3), 443-453. doi:10.1111/resp.12980

Anderson, G., & Takahama, Y. (2012). Thymic epithelial cells: working class heroes for T cell development and repertoire selection. Trends Immunol, 33(6), 256-263. doi:10.1016/j.it.2012.03.005

Anderson, K. L., Mulvihill, M. S., Speicher, P. J., Yerokun, B. A., Gulack, B. C., Nussbaum, D. P., . . . Hartwig, M. G. (2017). Adjuvant Chemotherapy Does Not Confer Superior Survival in Patients With Atypical Carcinoid Tumors. Ann Thorac Surg, 104(4), 1221-1230. doi:10.1016/j.athoracsur.2017.05.011

Ando, K., Akimoto, K., Sato, H., Manabe, R., Kishino, Y., Homma, T., . . . Sagara, H. (2020). Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer With or Without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis. Cancers (Basel), 12(4). doi:10.3390/cancers12040942

Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., . . . Investigators, P. (2018). Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med, 379(24), 2342-2350. doi:10.1056/NEJMoa1809697

Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., . . . Investigators, P. (2017). Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med, 377(20), 1919-1929. doi:10.1056/NEJMoa1709937

Arbour, K. C., Mezquita, L., Long, N., Rizvi, H., Auclin, E., Ni, A., . . . Hellmann, M. D. (2018). Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. J Clin Oncol, 36(28), 2872-2878. doi:10.1200/JCO.2018.79.0006

Arends, J., Bachmann, P., Baracos, V., Barthelemy, N., Bertz, H., Bozzetti, F., . . . Preiser, J. C. (2017). ESPEN guidelines on nutrition in cancer patients. Clin Nutr, 36(1), 11-48. doi:10.1016/j.clnu.2016.07.015

Arrieta, O., Cardona, A. F., Lara-Mejía, L., Heredia, D., Barrón, F., Zatarain-Barrón, Z. L., . . . Rosell, R. (2020). Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group. Crit Rev Oncol Hematol, 153, 103033. doi:10.1016/j.critrevonc.2020.103033

Arter, Z. L., & Nagasaka, M. (2024). The Nail in the Coffin?: Examining the KEYNOTE-789 Clinical Trial's Impact. Lung Cancer (Auckl), 15, 1-8. doi:10.2147/LCTT.S443099

Asamura, H., Chansky, K., Crowley, J., Goldstraw, P., Rusch, V. W., Vansteenkiste, J. F., . . . International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, A. v. B. M., and Participating Institutions. (2015). The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. J Thorac Oncol, 10(12), 1675-1684. doi:10.1097/JTO.0000000000000678

Asciak, R., Bedawi, E. O., Bhatnagar, R., Clive, A. O., Hassan, M., Lloyd, H., . . . Rahman, N. M. (2023). British Thoracic Society Clinical Statement on pleural procedures. Thorax, 78(Suppl 3), s43-s68. doi:10.1136/thorax-2022-219371

Ashworth, A. B., Senan, S., Palma, D. A., Riquet, M., Ahn, Y. C., Ricardi, U., . . . Rodrigues, G. B. (2014). An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer, 15(5), 346-355. doi:10.1016/j.cllc.2014.04.003

Auperin, A., Arriagada, R., Pignon, J. P., Le Pechoux, C., Gregor, A., Stephens, R. J., . . . Aisner, J. (1999). Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med, 341(7), 476-484.

Aupérin, A., Le Péchoux, C., Rolland, E., Curran, W. J., Furuse, K., Fournel, P., . . . Pignon, J. P. (2010). Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol, 28(13), 2181-2190. doi:10.1200/JCO.2009.26.2543

Avasarala, S. K., Lentz, R. J., & Maldonado, F. (2021). Medical Thoracoscopy. Clin Chest Med, 42(4), 751-766. doi:10.1016/j.ccm.2021.08.010

Awad, M. M., Oxnard, G. R., Jackman, D. M., Savukoski, D. O., Hall, D., Shivdasani, P., . . . Sholl, L. M. (2016). MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. J Clin Oncol. doi:10.1200/JCO.2015.63.4600

Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., . . . Giaccone, G. (2009). American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol, 27(36), 6251-6266.

Baas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., . . . Zalcman, G. (2021). First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet, 397(10272), 375-386. doi:10.1016/S0140-6736(20)32714-8

Baize, N., Monnet, I., Greillier, L., Geier, M., Lena, H., Janicot, H., . . . investigators, G. F. d. P.-C. (2020). Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol, 21(9), 1224-1233. doi:10.1016/S1470-2045(20)30461-7

Bankier, A. A., MacMahon, H., Goo, J. M., Rubin, G. D., Schaefer-Prokop, C. M., & Naidich, D. P. (2017). Recommendations for Measuring Pulmonary Nodules at CT: A Statement from the Fleischner Society. Radiology, 162894. doi:10.1148/radiol.2017162894

Barlesi, F., Vansteenkiste, J., Spigel, D., Ishii, H., Garassino, M., de Marinis, F., . . . Park, K. (2018). Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncol. doi:10.1016/S1470-2045(18)30673-9

Baudin, E., Caplin, M., Garcia-Carbonero, R., Fazio, N., Ferolla, P., Filosso, P. L., . . . Berruti, A. (2021). Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(☆). Ann Oncol, 32(4), 439-451. doi:10.1016/j.annonc.2021.01.003

Baudin, E., Caplin, M., Garcia-Carbonero, R., Fazio, N., Ferolla, P., Filosso, P. L., . . . clinicalguidelines@esmo.org, E. G. C. E. a. (2021). Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 32(4), 439-451. doi:10.1016/j.annonc.2021.01.003

Baumann, P., Nyman, J., Hoyer, M., Gagliardi, G., Lax, I., Wennberg, B., . . . Lewensohn, R. (2008). Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiother Oncol, 88(3), 359-367. doi:10.1016/j.radonc.2008.07.019

Baumann, P., Nyman, J., Hoyer, M., Wennberg, B., Gagliardi, G., Lax, I., . . . Lewensohn, R. (2009). Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol, 27(20), 3290-3296.

Belli, C., Anand, S., Gainor, J. F., Penault-Llorca, F., Subbiah, V., Drilon, A., . . . Curigliano, G. (2020). Progresses Toward Precision Medicine in  RET-altered Solid Tumors. Clin Cancer Res, 26(23), 6102-6111. doi:10.1158/1078-0432.CCR-20-1587

Benna, M., Guy, J. B., Bosacki, C., Jmour, O., Ben Mrad, M., Ogorodniitchouk, O., . . . Vallard, A. (2020). Chemoradiation and granulocyte-colony or granulocyte macrophage-colony stimulating factors (G-CSF or GM-CSF): time to think out of the box? Br J Radiol, 93(1109), 20190147. doi:10.1259/bjr.20190147

Berardi, R., De Lisa, M., Pagliaretta, S., Onofri, A., Morgese, F., Savini, A., . . . Cascinu, S. (2014). Thymic neoplasms: An update on the use of chemotherapy and new targeted therapies. A literature review. Cancer Treat Rev, 40(4), 495-506. doi:10.1016/j.ctrv.2013.11.003

Berry, M. F., D'Amico, T. A., Onaitis, M. W., & Kelsey, C. R. (2014). Thoracoscopic approach to lobectomy for lung cancer does not compromise oncologic efficacy. Ann Thorac Surg, 98(1), 197-202. doi:10.1016/j.athoracsur.2014.03.018

Bi, N., & Wang, L. (2015). Superiority of concomitant chemoradiation over sequential chemoradiation in inoperable, locally advanced non-small cell lung cancer: challenges in the selection of appropriate chemotherapy. Semin Radiat Oncol, 25(2), 122-132. doi:10.1016/j.semradonc.2014.11.003

Bilski, M., Mertowska, P., Mertowski, S., Sawicki, M., Hymos, A., Niedźwiedzka-Rystwej, P., & Grywalska, E. (2021). The Role of Conventionally Fractionated Radiotherapy and Stereotactic Radiotherapy in the Treatment of Carcinoid Tumors and Large-Cell Neuroendocrine Cancer of the Lung. Cancers (Basel), 14(1). doi:10.3390/cancers14010177

Bischof, M., Debus, J., Herfarth, K., Muley, T., Kappes, J., Storz, K., & Hoffmann, H. (2007). Surgery and chemotherapy for small cell lung cancer in stages I-II with or without radiotherapy. Strahlenther Onkol, 183(12), 679-684.

Bissett, D., Macbeth, F. R., & Cram, I. (1991). The role of palliative radiotherapy in malignant mesothelioma. Clin Oncol (R Coll Radiol), 3(6), 315-317.

Bolliger, C. T., Sutedja, T. G., Strausz, J., & Freitag, L. (2006). Therapeutic bronchoscopy with immediate effect: laser, electrocautery, argon plasma coagulation and stents. Eur Respir J, 27(6), 1258-1271.

Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., . . . Brahmer, J. R. (2015). Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med, 373(17), 1627-1639. doi:10.1056/NEJMoa1507643

Bossé, Y., & Amos, C. I. (2018). A Decade of GWAS Results in Lung Cancer. Cancer Epidemiol Biomarkers Prev, 27(4), 363-379. doi:10.1158/1055-9965.EPI-16-0794

Bousema, J. E., Dijkgraaf, M. G. W., van der Heijden, E., Verhagen, A., Annema, J. T., van den Broek, F. J. C., & group, M. E. s. (2023). Endosonography With or Without Confirmatory Mediastinoscopy for Resectable Lung Cancer: A Randomized Clinical Trial. J Clin Oncol, 41(22), 3805-3815. doi:10.1200/JCO.22.01728

Boyar Cetinkaya, R., Aagnes, B., Thiis-Evensen, E., Tretli, S., Bergestuen, D. S., & Hansen, S. (2017). Trends in Incidence of Neuroendocrine Neoplasms in Norway: A Report of 16,075 Cases from 1993 through 2010. Neuroendocrinology, 104(1), 1-10. doi:10.1159/000442207

Bradley, J., & Movsas, B. (2004). Radiation esophagitis: Predictive factors and preventive strategies. Semin Radiat Oncol, 14(4), 280-286. doi:10.1016/j.semradonc.2004.06.003

Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E., Poddubskaya, E., . . . Spigel, D. R. (2015). Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med, 373(2), 123-135. doi:10.1056/NEJMoa1504627

Brahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., Brufsky, J., Cappelli, L. C., Cortazar, F. B., . . . Ernstoff, M. S. (2021). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer, 9(6). doi:10.1136/jitc-2021-002435

Brcic, L., & Kern, I. (2020). Clinical significance of histologic subtyping of malignant pleural mesothelioma. Transl Lung Cancer Res, 9(3), 924-933. doi:10.21037/tlcr.2020.03.38

Brokx, H. A. P., Risse, E. K., Paul, M. A., Grunberg, K., Golding, R. P., Kunst, P. W. A., . . . Sutedja, T. G. (2007). Initial bronchoscopic treatment for patients with intraluminal bronchial carcinoids. J Thorac Cardiovasc Surg, 133(4), 973-978.

Brown, D. J. (2006). Palliation of breathlessness. Clin Med (Lond), 6(2), 133-136. doi:10.7861/clinmedicine.6-2-133

Brown, P. D., Ballman, K. V., Cerhan, J. H., Anderson, S. K., Carrero, X. W., Whitton, A. C., . . . Roberge, D. (2017). Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol, 18(8), 1049-1060. doi:10.1016/S1470-2045(17)30441-2

Brustugun, O. T., Grønberg, B. H., Fjellbirkeland, L., Helbekkmo, N., Aanerud, M., Grimsrud, T. K., . . . Solberg, S. K. (2018). Substantial nation-wide improvement in lung cancer relative survival in  Norway from 2000 to 2016   Lung Cancer, 122, 138-145.

Brustugun, O. T., Møller, B., & Helland, A. (2014). Years of life lost as a measure of cancer burden on a national level. Br J Cancer, 111(5), 1014-1020. doi:10.1038/bjc.2014.364

Brustugun, O. T., Nilssen, Y., & Eide, I. J. Z. (2021). Epidemiology and outcome of peritoneal and pleural mesothelioma subtypes in Norway. A 20 year nation-wide study. Acta Oncol, 60(10), 1250-1256. doi:10.1080/0284186X.2021.1955971

Bugge, A. S., Lund, M. B., Valberg, M., Brustugun, O. T., Solberg, S., & Kongerud, J. (2018). Cause-specific death after surgical resection for early-stage non-small-cell lung cancer. Eur J Cardiothorac Surg, 53(1), 221-227. doi:10.1093/ejcts/ezx274

Bunn, P. A., Crowley, J., Kelly, K., Hazuka, M. B., Beasley, K., Upchurch, C., . . . Gandara, D. R. (1995). Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol, 13(7), 1632-1641.

Bydder, S., Phillips, M., Joseph, D. J., Cameron, F., Spry, N. A., DeMelker, Y., & Musk, A. W. (2004). A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer, 91(1), 9-10.

Bydder, S., Spry, N. A., Christie, D. R. H., Roos, D., Burmeister, B. H., Krawitz, H., . . . Berry, M. (2003). A prospective trial of short-fractionation radiotherapy for the palliation of liver metastases. Australasian Radiology, 47(3), 284-288. doi:doi:10.1046/j.1440-1673.2003.01177.x

Callister, M. E., Baldwin, D. R., Akram, A. R., Barnard, S., Cane, P., Draffan, J., . . . British Thoracic Society Standards of Care, C. (2015). British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax, 70 Suppl 2, ii1-ii54. doi:10.1136/thoraxjnl-2015-207168

Calvert, M., Blazeby, J., Altman, D. G., Revicki, D. A., Moher, D., Brundage, M. D., & Group, C. P. (2013). Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA, 309(8), 814-822. doi:10.1001/jama.2013.879

Camidge, D. R., Kim, H. R., Ahn, M. J., Yang, J. C., Han, J. Y., Lee, J. S., . . . Popat, S. (2018). Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med, 379(21), 2027-2039. doi:10.1056/NEJMoa1810171

Camidge, D. R., Kim, H. R., Ahn, M. J., Yang, J. C. H., Han, J. Y., Hochmair, M. J., . . . Popat, S. (2020). Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. J Clin Oncol, 38(31), 3592-3603. doi:10.1200/JCO.20.00505

Camidge, D. R., Pabani, A., Miller, R. M., Rizvi, N. A., & Bazhenova, L. (2019). Management Strategies for Early-Onset Pulmonary Events Associated with Brigatinib. J Thorac Oncol, 14(9), 1547-1555. doi:10.1016/j.jtho.2019.04.028

Cannon, D. M., Mehta, M. P., Adkison, J. B., Khuntia, D., Traynor, A. M., Tomé, W. A., . . . Cannon, G. M. (2013). Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. J Clin Oncol, 31(34), 4343-4348. doi:10.1200/JCO.2013.51.5353

Cao, C. Q., Yan, T. D., Bannon, P. G., & McCaughan, B. C. (2010). A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol, 5(10), 1692-1703. doi:10.1097/JTO.0b013e3181ed0489

Caplin, M. E., Baudin, E., Ferolla, P., Filosso, P., Garcia-Yuste, M., Lim, E., . . . participants, E. c. c. (2015). Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. doi:10.1093/annonc/mdv041

Cardillo, G., Sera, F., Di Martino, M., Graziano, P., Giunti, R., Carbone, L., . . . Martelli, M. (2004). Bronchial carcinoid tumors: nodal status and long-term survival after resection. Ann Thorac Surg, 77(5), 1781-1785. doi:10.1016/j.athoracsur.2003.10.089

Carter, B. W., Benveniste, M. F., Madan, R., Godoy, M. C., de Groot, P. M., Truong, M. T., . . . Marom, E. M. (2017). ITMIG Classification of Mediastinal Compartments and Multidisciplinary Approach to Mediastinal Masses. Radiographics, 37(2), 413-436. doi:10.1148/rg.2017160095

Carter, B. W., Benveniste, M. F., Madan, R., Godoy, M. C., Groot, P. M., Truong, M. T., . . . Marom, E. M. (2017). IASLC/ITMIG Staging System and Lymph Node Map for Thymic Epithelial Neoplasms. Radiographics, 37(3), 758-776. doi:10.1148/rg.2017160096

Castello, A., Rossi, S., & Lopci, E. (2020). 18F-FDG PET/CT in Restaging and Evaluation of Response to Therapy in Lung Cancer: State of the Art. Curr Radiopharm, 13(3), 228-237. doi:10.2174/1874471013666191230144821

Cavaliere, S., Venuta, F., Foccoli, P., Toninelli, C., & La Face, B. (1996). Endoscopic treatment of malignant airway obstructions in 2,008 patients. Chest, 110(6), 1536-1542.

Cañizares, M. A., Matilla, J. M., Cueto, A., Algar, J., Muguruza, I., Moreno-Mata, N., . . . Members, E.-S. (2014). Atypical carcinoid tumours of the lung: prognostic factors and patterns of recurrence. Thorax, 69(7), 648-653. doi:10.1136/thoraxjnl-2013-204102

Chakrabarty, N., Mahajan, A., Patil, V., Noronha, V., & Prabhash, K. (2023). Imaging of brain metastasis in non-small-cell lung cancer: indications, protocols, diagnosis, post-therapy imaging, and implications regarding management. Clin Radiol, 78(3), 175-186. doi:10.1016/j.crad.2022.09.134

Chandrasekar, D., Tribett, E., & Ramchandran, K. (2016). Integrated Palliative Care and Oncologic Care in Non-Small-Cell Lung Cancer. Curr Treat Options Oncol, 17(5), 23. doi:10.1007/s11864-016-0397-1

Chang, J. Y., Senan, S., Paul, M. A., Mehran, R. J., Louie, A. V., Balter, P., . . . Roth, J. A. (2015). Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. doi:10.1016/S1470-2045(15)70168-3

Chapel, D. B., Schulte, J. J., Husain, A. N., & Krausz, T. (2020). Application of immunohistochemistry in diagnosis and management of malignant mesothelioma. Transl Lung Cancer Res, 9(Suppl 1), S3-S27. doi:10.21037/tlcr.2019.11.29

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. (1995). BMJ, 311(7010), 899-909.

Chen, G., Huynh, M., Chen, A., Fehrenbacher, L., Gandara, D., & Lau, D. (2008). Chemotherapy for brain metastases in small-cell lung cancer. Clin Lung Cancer, 9(1), 35-38.

Chen, G., Huynh, M., Fehrenbacher, L., West, H., Lara, P. N., Yavorkovsky, L. L., . . . Lau, D. (2009). Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. J Clin Oncol, 27(9), 1401-1404. doi:10.1200/JCO.2008.20.2127

Chen, L., Shen, C., Redmond, K. J., Page, B. R., Kummerlowe, M., Mcnutt, T., . . . Kleinberg, L. (2017). Use of Stereotactic Radiosurgery in Elderly and Very Elderly Patients With Brain Metastases to Limit Toxicity Associated With Whole Brain Radiation Therapy. Int J Radiat Oncol Biol Phys, 98(4), 939-947. doi:10.1016/j.ijrobp.2017.02.031

Cheng, S., Evans, W. K., Stys-Norman, D., & Shepherd, F. A. (2007). Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol, 2(4), 348-354.

Cherny, N. I., Catane, R., Kosmidis, P., & Care, E. T. o. S. a. P. (2003). ESMO takes a stand on supportive and palliative care. Ann Oncol, 14(9), 1335-1337. doi:10.1093/annonc/mdg379

Chiu, C. H., Chern, M. S., Wu, M. H., Hsu, W. H., Wu, Y. C., Huang, M. H., & Chang, S. C. (2003). Usefulness of low-dose spiral CT of the chest in regular follow-up of postoperative non-small cell lung cancer patients: Preliminary report. J Thorac Cardiovasc Surg, 125(6), 1300-1305.

Cho, J., Kim, H. S., Ku, B. M., Choi, Y. L., Cristescu, R., Han, J., . . . Ahn, M. J. (2018). Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. J Clin Oncol, JCO2017773184. doi:10.1200/JCO.2017.77.3184

Cho, J. H., Lim, S. H., An, H. J., Kim, K. H., Park, K. U., Kang, E. J., . . . Ahn, M. J. (2020). Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). J Clin Oncol, 38(5), 488-495. doi:10.1200/JCO.19.00931

Christensen, N. L., Jekunen, A., Heinonen, S., Dalton, S. O., & Rasmussen, T. R. (2017). Lung cancer guidelines in Sweden, Denmark, Norway and Finland: a comparison. Acta Oncol, 56(7), 943-948. doi:10.1080/0284186X.2017.1315172

Chung, H. C., Piha-Paul, S. A., Lopez-Martin, J., Schellens, J. H. M., Kao, S., Miller, W. H., . . . Ott, P. A. (2020). Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. J Thorac Oncol, 15(4), 618-627. doi:10.1016/j.jtho.2019.12.109

Ciuleanu, T., Stelmakh, L., Cicenas, S., Miliauskas, S., Grigorescu, A. C., Hillenbach, C., . . . Gonzalez, E. E. (2012). Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol, 13(3), 300-308. doi:10.1016/S1470-2045(11)70385-0

Colt, H. G., Murgu, S. D., Korst, R. J., Slatore, C. G., Unger, M., & Quadrelli, S. (2013). Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 143(5 Suppl), e437S-454S. doi:10.1378/chest.12-2365

Crona, J., Fanola, I., Lindholm, D. P., Antonodimitrakis, P., Öberg, K., Eriksson, B., & Granberg, D. (2013). Effect of temozolomide in patients with metastatic bronchial carcinoids. Neuroendocrinology, 98(2), 151-155. doi:10.1159/000354760

Cuffe, S., Booth, C. M., Peng, Y., Darling, G. E., Li, G., Kong, W., . . . Shepherd, F. A. (2012). Adjuvant chemotherapy for non-small-cell lung cancer in the elderly: a population-based study in Ontario, Canada. J Clin Oncol, 30(15), 1813-1821. doi:10.1200/JCO.2011.39.3330

Dagogo-Jack, I., Moonsamy, P., Gainor, J. F., Lennerz, J. K., Piotrowska, Z., Lin, J. J., . . . Heist, R. S. (2021). A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. J Thorac Oncol, 16(5), 850-859. doi:10.1016/j.jtho.2021.01.1605

Dam, G., Grønbæk, H., Sundlöv, A., Botling, J., Sundin, A., Petersen, R. H., . . . Langer, S. W. (2023). Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms. Acta Oncol, 62(5), 431-437. doi:10.1080/0284186x.2023.2212411

Damirov, F., Büsing, K., Yavuz, G., Hatz, R., Manapov, F., Michels, J., . . . Roessner, E. (2023). Preoperative Hilar and Mediastinal Lymph Node Staging in Patients with Suspected or Diagnosed Lung Cancer: Accuracy of 18F-FDG-PET/CT:A Retrospective Cohort Study of 138 Patients. Diagnostics (Basel), 13(3). doi:10.3390/diagnostics13030403

Damirov, F., Stoleriu, M. G., Manapov, F., Büsing, K., Michels, J. D., Preissler, G., . . . Roessner, E. D. (2023). Histology of the Primary Tumor Correlates with False Positivity of Integrated 18F-FDG-PET/CT Lymph Node Staging in Resectable Lung Cancer Patients. Diagnostics (Basel), 13(11). doi:10.3390/diagnostics13111893

de Alencar, V. T. L., Formiga, M. N., & de Lima, V. C. C. (2020). Inherited lung cancer: a review. Ecancermedicalscience, 14, 1008. doi:10.3332/ecancer.2020.1008

de Koning, H. J., van der Aalst, C. M., de Jong, P. A., Scholten, E. T., Nackaerts, K., Heuvelmans, M. A., . . . Oudkerk, M. (2020). Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med, 382(6), 503-513. doi:10.1056/NEJMoa1911793

De Leyn, P., Dooms, C., Kuzdzal, J., Lardinois, D., Passlick, B., Rami-Porta, R., . . . Zielinski, M. (2014). Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg. doi:10.1093/ejcts/ezu028

de Perrot, M., Feld, R., Cho, B. C., Bezjak, A., Anraku, M., Burkes, R., . . . Johnston, M. R. (2009). Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol, 27(9), 1413-1418. doi:10.1200/JCO.2008.17.5604

De Ruysscher, D., Botterweck, A., Dirx, M., Pijls-Johannesma, M., Wanders, R., Hochstenbag, M., . . . Lambin, P. (2009). Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol, 20(1), 98-102. doi:10.1093/annonc/mdn559

De Ruysscher, D., Nakagawa, K., & Asamura, H. (2014). Surgical and nonsurgical approaches to small-size nonsmall cell lung cancer. Eur Respir J, 44(2), 483-494. doi:10.1183/09031936.00020214

De Ruysscher, D., & Slotman, B. (2003). Treatment of intervention sites of malignant pleural mesothelioma with radiotherapy: a Dutch-Belgian survey. Radiotherapy and Oncology, 68(3), 299-302.

Desai, R., Koipallil, G. K., Thomas, N., Mhaskar, R., Visweshwar, N., Laber, D., . . . Jaglal, M. (2020). Efficacy and safety of direct oral anticoagulants for secondary prevention of cancer associated thrombosis: a meta-analysis of randomized controlled trials. Sci Rep, 10(1), 18945. doi:10.1038/s41598-020-75863-3

Detterbeck, F. C. (2010). Management of carcinoid tumors. Ann Thorac Surg, 89(3), 998-1005. doi:10.1016/j.athoracsur.2009.07.097

Detterbeck, F. C., Nicholson, A. G., Franklin, W. A., Marom, E. M., Travis, W. D., Girard, N., . . . Institutions, P. (2016). The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. J Thorac Oncol, 11(5), 639-650. doi:10.1016/j.jtho.2016.01.024

Detterbeck, F. C., Nicholson, A. G., Kondo, K., Van Schil, P., & Moran, C. (2011). The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms. J Thorac Oncol, 6(7 Suppl 3), S1710-1716. doi:10.1097/JTO.0b013e31821e8cff

Dingemans, A. C., Hendriks, L. E. L., Berghmans, T., Levy, A., Hasan, B., Faivre-Finn, C., . . . Novello, S. (2019). Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report. J Thorac Oncol, 14(12), 2109-2119. doi:10.1016/j.jtho.2019.07.025

Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., . . . investigators, t. (2020). Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol, 21(2), 271-282. doi:10.1016/S1470-2045(19)30691-6

Doebele, R. C., Perez, L., Trinh, H., Martinec, M., Martina, R., Riehl, T., . . . Crane, G. (2021). Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in. J Comp Eff Res, 10(17), 1271-1282. doi:10.2217/cer-2021-0131

Dominioni, L., Rotolo, N., Mantovani, W., Poli, A., Pisani, S., Conti, V., . . . Imperatori, A. (2012). A population-based cohort study of chest x-ray screening in smokers: lung cancer detection findings and follow-up. BMC Cancer, 12, 18. doi:10.1186/1471-2407-12-18

Drilon, A., Oxnard, G. R., Tan, D. S. W., Loong, H. H. F., Johnson, M., Gainor, J., . . . Subbiah, V. (2020). Efficacy of Selpercatinib in in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med, 383(9), 813-824. doi:10.1056/NEJMoa2005653

Drilon, A., Siena, S., Dziadziuszko, R., Barlesi, F., Krebs, M. G., Shaw, A. T., . . . investigators, t. (2020). Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol, 21(2), 261-270. doi:10.1016/S1470-2045(19)30690-4

Drilon, A., Siena, S., Ou, S. I., Patel, M., Ahn, M. J., Lee, J., . . . De Braud, F. G. (2017). Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov, 7(4), 400-409. doi:10.1158/2159-8290.CD-16-1237

Drilon, A., Subbiah, V., Gautschi, O., Tomasini, P., de Braud, F., Solomon, B. J., . . . Besse, B. (2023). Selpercatinib in Patients With RET fusion–positive non–small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I/II trial. J Clin Oncol, 41(2), 385-394. doi:10.1200/JCO.22.00393

Dunne, E. G., Fick, C. N., & Jones, D. R. (2023). Mediastinal Staging in Non-Small-Cell Lung Cancer: Saying Goodbye to Mediastinoscopy. J Clin Oncol, 41(22), 3785-3790. doi:10.1200/JCO.23.00867

Dziadziuszko, R., Krebs, M. G., De Braud, F., Siena, S., Drilon, A., Doebele, R. C., . . . Barlesi, F. (2021). Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic. J Clin Oncol, 39(11), 1253-1263. doi:10.1200/JCO.20.03025

Eblan, M. J., Corradetti, M. N., Lukens, J. N., Xanthopoulos, E., Mitra, N., Christodouleas, J. P., . . . Apisarnthanarax, S. (2013). Brachial plexopathy in apical non-small cell lung cancer treated with definitive radiation: dosimetric analysis and clinical implications. Int J Radiat Oncol Biol Phys, 85(1), 175-181. doi:10.1016/j.ijrobp.2012.03.051

Edvardsen, E., Skjønsberg, O. H., Holme, I., Nordsletten, L., Borchsenius, F., & Anderssen, S. A. (2015). High-intensity training following lung cancer surgery: a randomised controlled trial. Thorax, 70(3), 244-250. doi:10.1136/thoraxjnl-2014-205944

Eguren-Santamaria, I., Sanmamed, M. F., Goldberg, S. B., Kluger, H. M., Idoate, M. A., Lu, B. Y., . . . Gil-Bazo, I. (2020). PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice. Clin Cancer Res, 26(16), 4186-4197. doi:10.1158/1078-0432.CCR-20-0798

Eide, I. J. Z., Stensgaard, S., Helland, Å., Ekman, S., Mellemgaard, A., Hansen, K. H., . . . Brustugun, O. T. (2022). Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials. Transl Lung Cancer Res, 11(6), 953-963. doi:10.21037/tlcr-21-995

El Zarif, T., Nassar, A. H., Adib, E., Fitzgerald, B. G., Huang, J., Mouhieddine, T. H., . . . Naqash, A. R. (2023). Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. J Clin Oncol, 41(21), 3712-3723. doi:10.1200/JCO.22.02459

El-Sherief, A. H., Lau, C. T., Carter, B. W., & Wu, C. C. (2018). Staging Lung Cancer: Regional Lymph Node Classification. Radiol Clin North Am, 56(3), 399-409. doi:10.1016/j.rcl.2018.01.008

Ellis, P., Davies, A. M., Evans, W. K., Haynes, A. E., Lloyd, N. S., & Care, L. C. D. S. G. o. C. C. O. s. P. i. E.-b. (2006). The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol, 1(6), 591-601.

Ernst, A., Feller-Kopman, D., Becker, H. D., & Mehta, A. C. (2004). Central airway obstruction. Am J Respir Crit Care Med, 169(12), 1278-1297.

Eze, C., Käsmann, L., & Manapov, F. (2019). Redefining the Role of Prophylactic Cranial Irradiation in the Modern Era of Active Surveillance in Small Cell Lung Cancer. JAMA Oncol, 5(1), 11-12. doi:10.1001/jamaoncol.2018.4833

Fairchild, A., Harris, K., Barnes, E., Wong, R., Lutz, S., Bezjak, A., . . . Chow, E. (2008). Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol, 26(24), 4001-4011.

Faivre-Finn, C., Snee, M., Ashcroft, L., Appel, W., Barlesi, F., Bhatnagar, A., . . . Team, C. S. (2017). Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol, 18(8), 1116-1125. doi:10.1016/S1470-2045(17)30318-2

Falcoz, P. E., Puyraveau, M., Thomas, P. A., Decaluwe, H., Hürtgen, M., Petersen, R. H., . . . Group, E. D. C. a. E. M. I. I. (2015). Video-assisted thoracoscopic surgery versus open lobectomy for primary non-small-cell lung cancer: a propensity-matched analysis of outcome from the European Society of Thoracic Surgeon database. Eur J Cardiothorac Surg. doi:10.1093/ejcts/ezv154

Falk, S. J., Girling, D. J., White, R. J., Hopwood, P., Harvey, A., Qian, W., & Stephens, R. J. (2002). Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial. BMJ, 325(7362), 465-465.

Falkson, C. B., Bezjak, A., Darling, G., Gregg, R., Malthaner, R., Maziak, D. E., . . . Care, L. C. D. S. G. o. C. C. O. s. P. i. E.-B. (2009). The management of thymoma: a systematic review and practice guideline. J Thorac Oncol, 4(7), 911-919.

Falkson, C. B., Vella, E. T., Ellis, P. M., Maziak, D. E., Ung, Y. C., & Yu, E. (2022). Surgical, Radiation, and Systemic Treatments of Patients with Thymic Epithelial Tumours: A Clinical Practice Guideline. J Thorac Oncol. doi:10.1016/j.jtho.2022.08.007

Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., . . . Group, P. S. (2016). Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet, 387(10030), 1837-1846. doi:10.1016/S0140-6736(16)00587-0

Felip, E., Altorki, N., Zhou, C., Csőszi, T., Vynnychenko, I., Goloborodko, O., . . . Investigators, I. (2021). Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. doi:10.1016/S0140-6736(21)02098-5

Felip, E., Rosell, R., Maestre, J. A., Rodríguez-Paniagua, J. M., Morán, T., Astudillo, J., . . . Group, S. L. C. (2010). Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol, 28(19), 3138-3145. doi:10.1200/JCO.2009.27.6204

Fennell, D. A., Ewings, S., Ottensmeier, C., Califano, R., Hanna, G. G., Hill, K., . . . investigators, C. t. (2021). Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol, 22(11), 1530-1540. doi:10.1016/S1470-2045(21)00471-X

Ferguson, M. K., & Lehman, A. G. (2003). Sleeve lobectomy or pneumonectomy: optimal management strategy using decision analysis techniques. Ann Thorac Surg, 76(6), 1782-1788.

Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021). Cancer statistics for the year 2020: An overview. Int J Cancer. doi:10.1002/ijc.33588

Fernandez-Cuesta, L., Peifer, M., Lu, X., Sun, R., Ozretić, L., Seidel, D., . . . Thomas, R. K. (2014). Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nat Commun, 5, 3518. doi:10.1038/ncomms4518

Ferrara, M. G., Stefani, A., Simbolo, M., Pilotto, S., Martini, M., Lococo, F., . . . Bria, E. (2021). Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities. Front Oncol, 11, 650293. doi:10.3389/fonc.2021.650293

Ferris, F. D., Bruera, E., Cherny, N., Cummings, C., Currow, D., Dudgeon, D., . . . Von Roenn, J. H. (2009). Palliative cancer care a decade later: accomplishments, the need, next steps -- from the American Society of Clinical Oncology. J Clin Oncol, 27(18), 3052-3058. doi:10.1200/JCO.2008.20.1558

Filosso, P. L., Oliaro, A., Ruffini, E., Bora, G., Lyberis, P., Asioli, S., . . . Guerrera, F. (2013). Outcome and prognostic factors in bronchial carcinoids: a single-center experience. J Thorac Oncol, 8(10), 1282-1288. doi:10.1097/JTO.0b013e31829f097a

Filosso, P. L., Yao, X., Ruffini, E., Ahmad, U., Antonicelli, A., Huang, J., . . . Korst, R. (2016). Comparison of outcomes between neuroendocrine thymic tumours and other subtypes of thymic carcinomas: a joint analysis of the European Society of Thoracic Surgeons and the International Thymic Malignancy Interest Group. Eur J Cardiothorac Surg, 50(4), 766-771. doi:10.1093/ejcts/ezw107

Fink, G., Krelbaum, T., Yellin, A., Bendayan, D., Saute, M., Glazer, M., & Kramer, M. R. (2001). Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest, 119(6), 1647-1651.

Fogh, S., & Yom, S. S. (2014). Symptom management during the radiation oncology treatment course: a practical guide for the oncology clinician. Semin Oncol, 41(6), 764-775. doi:10.1053/j.seminoncol.2014.09.020

Folch, E. E., Labarca, G., Ospina-Delgado, D., Kheir, F., Majid, A., Khandhar, S. J., . . . Fernandez-Bussy, S. (2020). Sensitivity and Safety of Electromagnetic Navigation Bronchoscopy for Lung Cancer Diagnosis: Systematic Review and Meta-analysis. Chest, 158(4), 1753-1769. doi:10.1016/j.chest.2020.05.534

Forde, P. M., Spicer, J., & Girard, N. (2022). Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. Reply. N Engl J Med, 387(6), 572-573. doi:10.1056/NEJMc2208133

Foster, C. C., Rusthoven, C. G., Sher, D. J., Feldman, L., Pasquinelli, M., Spiotto, M. T., & Koshy, M. (2019). Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall: A National Cancer Database Analysis. Lung Cancer, 130, 162-168. doi:10.1016/j.lungcan.2019.02.023

Francis, S., Orton, A., Stoddard, G., Tao, R., Hitchcock, Y. J., Akerley, W., & Kokeny, K. E. (2017). Sequencing of Postoperative Radiotherapy and Chemotherapy for Locally Advanced or Incompletely Resected Non-Small-Cell Lung Cancer. J Clin Oncol, JCO2017744771. doi:10.1200/JCO.2017.74.4771

Früh, M., De Ruysscher, D., Popat, S., Crinò, L., Peters, S., Felip, E., & Group, E. G. W. (2013). Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 24 Suppl 6, vi99-105. doi:10.1093/annonc/mdt178

Fujii, Y. (2011). Published guidelines for management of thymoma. Thorac Surg Clin, 21(1), 125-129, viii. doi:10.1016/j.thorsurg.2010.08.002

Gadgeel, S., Rodríguez-Abreu, D., Speranza, G., Esteban, E., Felip, E., Dómine, M., . . . Garassino, M. C. (2020). Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol, 38(14), 1505-1517. doi:10.1200/JCO.19.03136

Gadgeel, S. M., Shaw, A. T., Govindan, R., Gandhi, L., Socinski, M. A., Camidge, D. R., . . . Ou, S. I. (2016). Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. J Clin Oncol, 34(34), 4079-4085. doi:10.1200/JCO.2016.68.4639

Gaebe, K., Erickson, A. W., Li, A. Y., Youssef, A. N., Sharma, B., Chan, K. K. W., . . . Das, S. (2024). Re-examining prophylactic cranial irradiation in small cell lung cancer: a systematic review and meta-analysis. EClinicalMedicine, 67, 102396. doi:10.1016/j.eclinm.2023.102396

Gainor, J. F., Curigliano, G., Kim, D. W., Lee, D. H., Besse, B., Baik, C. S., . . . Subbiah, V. (2021). Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol, 22(7), 959-969. doi:10.1016/S1470-2045(21)00247-3

Gandhi, L., & Garassino, M. C. (2018). Pembrolizumab plus Chemotherapy in Lung Cancer. N Engl J Med, 379(11), e18. doi:10.1056/NEJMc1808567

Garassino, M. C., Mazieres, J., Reck, M., Chouaid, C., Bischoff, H., Reinmuth, N., . . . Faivre-Finn, C. (2022). Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial. J Thorac Oncol. doi:10.1016/j.jtho.2022.07.1148

Garon, E. B., Ciuleanu, T. E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., . . . Pérol, M. (2014). Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet, 384(9944), 665-673. doi:10.1016/S0140-6736(14)60845-X

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., . . . Investigators, K.-. (2015). Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med, 372(21), 2018-2028. doi:10.1056/NEJMoa1501824

Genova, C., Rijavec, E., & Grossi, F. (2016). Hematopoietic growth factors in lung cancer. Curr Opin Oncol, 28(2), 135-144. doi:10.1097/CCO.0000000000000268

George, J., Walter, V., Peifer, M., Alexandrov, L. B., Seidel, D., Leenders, F., . . . Thomas, R. K. (2018). Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nat Commun, 9(1), 1048. doi:10.1038/s41467-018-03099-x

George, R., Jeba, J., Ramkumar, G., Chacko, A. G., & Tharyan, P. (2015). Interventions for the treatment of metastatic extradural spinal cord compression in adults. Cochrane Database Syst Rev(9), CD006716. doi:10.1002/14651858.CD006716.pub3

Gettinger, S., Horn, L., Jackman, D., Spigel, D., Antonia, S., Hellmann, M., . . . Brahmer, J. (2018). Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. J Clin Oncol, 36(17), 1675-1684. doi:10.1200/JCO.2017.77.0412

Gibson, A. J. W., Pabani, A., Dean, M. L., Martos, G., Cheung, W. Y., & Navani, V. (2023). Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in. JTO Clin Res Rep, 4(3), 100460. doi:10.1016/j.jtocrr.2022.100460

Gillespie, C. S., Mustafa, M. A., Richardson, G. E., Alam, A. M., Lee, K. S., Hughes, D. M., . . . Zakaria, R. (2023). Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis. J Thorac Oncol, 18(12), 1703-1713. doi:10.1016/j.jtho.2023.06.017

Girard, N., Ruffini, E., Marx, A., Faivre-Finn, C., Peters, S., & Committee, E. G. (2015). Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 26 Suppl 5, v40-55. doi:10.1093/annonc/mdv277

Gollard, R., Jhatakia, S., Elliott, M., & Kosty, M. (2010). Large cell/neuroendocrine carcinoma. Lung Cancer, 69(1), 13-18. doi:10.1016/j.lungcan.2009.12.011

Gomes, F., Faivre-Finn, C., Mistry, H., Bezjak, A., Pourel, N., Fournel, P., . . . Blackhall, F. (2021). Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial. Lung Cancer, 153, 165-170. doi:10.1016/j.lungcan.2021.01.025

Gomez, D. R., Tang, C., Zhang, J., Blumenschein, G. R., Hernandez, M., Lee, J. J., . . . Heymach, J. V. (2019). Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol, 37(18), 1558-1565. doi:10.1200/JCO.19.00201

Gorenberg, M., Bar-Shalom, R., & Israel, O. (2008). Patterns of FDG uptake in post-thoracotomy surgical scars in patients with lung cancer. Br J Radiol, 81(970), 821-825. doi:10.1259/bjr/26210052

Gould, M. K., Donington, J., Lynch, W. R., Mazzone, P. J., Midthun, D. E., Naidich, D. P., & Wiener, R. S. (2013). Evaluation of Individuals With Pulmonary Nodules: When Is It Lung Cancer?: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 143(5 Suppl), e93S-e120S. doi:10.1378/chest.12-2351

Graabak, G., Grønberg, B. H., Sandvei, M. S., Nilssen, Y., & Halvorsen, T. O. (2022). Thoracic Radiotherapy in Limited-Stage SCLC-a Population-Based Study of Patterns of Care in Norway From 2000 Until 2018. JTO Clin Res Rep, 3(2), 100270. doi:10.1016/j.jtocrr.2021.100270

Granberg, D., Eriksson, B., Wilander, E., Grimfjärd, P., Fjällskog, M. L., Oberg, K., & Skogseid, B. (2001). Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol, 12(10), 1383-1391.

Grassi, L., Nanni, M. G., Rodin, G., Li, M., & Caruso, R. (2018). The use of antidepressants in oncology: a review and practical tips for oncologists. Ann Oncol, 29(1), 101-111. doi:10.1093/annonc/mdx526

Gridelli, C., Ardizzoni, A., Ciardiello, F., Hanna, N., Heymach, J. V., Perrone, F., . . . De Marinis, F. (2008). Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol, 3(4), 430-440.

Griesinger, F., Curigliano, G., Thomas, M., Subbiah, V., Baik, C. S., Tan, D. S. W., . . . Mazières, J. (2022). Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Ann Oncol, 33(11), 1168-1178. doi:10.1016/j.annonc.2022.08.002

Grønberg, B. H., Halvorsen, T. O., Fløtten, Ø., Brustugun, O. T., Brunsvig, P. F., Aasebø, U., . . . Group, N. L. C. S. (2016). Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer. Acta Oncol, 55(5), 591-597. doi:10.3109/0284186X.2015.1092584

Grønberg, B. H., Killingberg, K. T., Fløtten, Ø., Brustugun, O. T., Hornslien, K., Madebo, T., . . . Halvorsen, T. O. (2021). High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet Oncol, 22(3), 321-331. doi:10.1016/S1470-2045(20)30742-7

Grøndahl, V., Binderup, T., Langer, S. W., Petersen, R. H., Nielsen, K., Kjaer, A., . . . Knigge, U. (2019). Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence. Lung Cancer, 132, 141-149. doi:10.1016/j.lungcan.2019.03.013

Guckenberger, M., Mantel, F., Gerszten, P. C., Flickinger, J. C., Sahgal, A., Létourneau, D., . . . Kersh, R. (2014). Safety and efficacy of stereotactic body radiotherapy as primary treatment for vertebral metastases: a multi-institutional analysis. Radiat Oncol, 9, 226. doi:10.1186/s13014-014-0226-2

Guisier, F., Dubos-Arvis, C., Viñas, F., Doubre, H., Ricordel, C., Ropert, S., . . . Bylicki, O. (2020). Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018. J Thorac Oncol, 15(4), 628-636. doi:10.1016/j.jtho.2019.12.129

Gulstene, S., Ruwanpura, T., Palma, D., & Joseph, N. (2022). Stereotactic Ablative Radiotherapy in the Treatment of Early-Stage Lung Cancer - A Done Deal? Clin Oncol (R Coll Radiol), 34(11), 733-740. doi:10.1016/j.clon.2022.08.027

Ha, D., Mazzone, P. J., Ries, A. L., Malhotra, A., & Fuster, M. (2016). The Utility of Exercise Testing in Patients with Lung Cancer. J Thorac Oncol, 11(9), 1397-1410. doi:10.1016/j.jtho.2016.04.021

Haldorsen, T., Andersen, A., & Boffetta, P. (2004). Smoking-adjusted incidence of lung cancer by occupation among Norwegian men. Cancer Causes Control, 15(2), 139-147. doi:10.1023/B:CACO.0000019485.74818.d6

Hallifax, R. J., Talwar, A., Wrightson, J. M., Edey, A., & Gleeson, F. V. (2017). State-of-the-art: Radiological investigation of pleural disease. Respir Med, 124, 88-99. doi:10.1016/j.rmed.2017.02.013

Hamaji, M., Kojima, F., Omasa, M., Sozu, T., Sato, T., Chen, F., . . . Date, H. (2015). A meta-analysis of debulking surgery versus surgical biopsy for unresectable thymoma. Eur J Cardiothorac Surg, 47(4), 602-607. doi:10.1093/ejcts/ezu277

Hansell, D. M., Bankier, A. A., MacMahon, H., McLoud, T. C., Müller, N. L., & Remy, J. (2008). Fleischner Society: glossary of terms for thoracic imaging. Radiology, 246(3), 697-722. doi:10.1148/radiol.2462070712

Harpole, D. H., Feldman, J. M., Buchanan, S., Young, W. G., & Wolfe, W. G. (1992). Bronchial carcinoid tumors: a retrospective analysis of 126 patients. Ann Thorac Surg, 54(1), 50-54; discussion 54-55.

Hassan, R., Morrow, B., Thomas, A., Walsh, T., Lee, M. K., Gulsuner, S., . . . Churpek, J. E. (2019). Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc Natl Acad Sci U S A, 116(18), 9008-9013. doi:10.1073/pnas.1821510116

Helbekkmo, N., Sundstrom, S. H., Aasebo, U., Brunsvig, P. F., von Plessen, C., Hjelde, H. H., . . . Bremnes, R. M. (2007). Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer, 97(3), 283-289. doi:6603869 [pii] 10.1038/sj.bjc.6603869

Helland, Å., Solberg, S., & Brustugun, O. T. (2012). Incidence and survival of malignant pleural mesothelioma in norway: a population-based study of 1686 cases. J Thorac Oncol, 7(12), 1858-1861. doi:10.1097/JTO.0b013e318275b346

Hendriks, L. E., Hermans, B. C., van den Beuken-van Everdingen, M. H., Hochstenbag, M. M., & Dingemans, A. M. (2016). Effect of Bisphosphonates, Denosumab, and Radioisotopes on Bone Pain and Quality of Life in Patients with Non-Small Cell Lung Cancer and Bone Metastases: A Systematic Review. J Thorac Oncol, 11(2), 155-173. doi:10.1016/j.jtho.2015.10.001

Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., . . . clinicalguidelines@esmo.org, E. G. C. E. a. (2023). Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol, 34(4), 358-376. doi:10.1016/j.annonc.2022.12.013

Herbst, R. S., Baas, P., Kim, D. W., Felip, E., Pérez-Gracia, J. L., Han, J. Y., . . . Garon, E. B. (2016). Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, 387(10027), 1540-1550. doi:10.1016/S0140-6736(15)01281-7

Herbst, R. S., Giaccone, G., de Marinis, F., Reinmuth, N., Vergnenegre, A., Barrios, C. H., . . . Spigel, D. R. (2020). Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med, 383(14), 1328-1339. doi:10.1056/NEJMoa1917346

Herder, G. J., van Tinteren, H., Golding, R. P., Kostense, P. J., Comans, E. F., Smit, E. F., & Hoekstra, O. S. (2005). Clinical prediction model to characterize pulmonary nodules: validation and added value of 18F-fluorodeoxyglucose positron emission tomography. Chest, 128(4), 2490-2496. doi:10.1378/chest.128.4.2490

Heymach, J. V., Harpole, D., Mitsudomi, T., Taube, J. M., Galffy, G., Hochmair, M., . . . Investigators, A. (2023). Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. N Engl J Med, 389(18), 1672-1684. doi:10.1056/NEJMoa2304875

Hishida, T., Nagai, K., Yoshida, J., Nishimura, M., Ishii, G.-i., Iwasaki, M., & Nishiwaki, Y. (2006). Is surgical resection indicated for a solitary non-small cell lung cancer recurrence? J Thorac Cardiovasc Surg, 131(4), 838-842.

Hochmair, M., Weinlinger, C., Schwab, S., Naber, J., Setinek, U., Krenbek, D., . . . Burghuber, O. C. (2019). Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution. Anticancer Drugs, 30(7), e0787. doi:10.1097/CAD.0000000000000787

Hollevoet, K., Reitsma, J. B., Creaney, J., Grigoriu, B. D., Robinson, B. W., Scherpereel, A., . . . van Meerbeeck, J. P. (2012). Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol, 30(13), 1541-1549. doi:10.1200/JCO.2011.39.6671

Holsti, L. R., Pyrhonen, S., Kajanti, M., Mantyla, M., Mattson, K., Maasilta, P., & Kivisaari, L. (1997). Altered fractionation of hemithorax irradiation for pleural mesothelioma and failure patterns after treatment. Acta Oncol, 36(4), 397-405.

Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., . . . Drilon, A. (2020). Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol, 21(4), 531-540. doi:10.1016/S1470-2045(19)30856-3

Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., . . . Group, I. S. (2018). First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med, 379(23), 2220-2229. doi:10.1056/NEJMoa1809064

Hotta, K., Matsuo, K., Ueoka, H., Kiura, K., Tabata, M., & Tanimoto, M. (Writers). (2004). Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. In.

Huang, J., Detterbeck, F. C., Wang, Z., & Loehrer, P. J. (2011). Standard outcome measures for thymic malignancies. J Thorac Oncol, 6(7 Suppl 3), S1691-1697. doi:10.1097/JTO.0b013e3182254ac1

Huber, R. M., Hansen, K. H., Paz-Ares Rodríguez, L., West, H. L., Reckamp, K. L., Leighl, N. B., . . . Camidge, D. R. (2020). Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. J Thorac Oncol, 15(3), 404-415. doi:10.1016/j.jtho.2019.11.004

Hui, D., & Bruera, E. (2016). Integrating palliative care into the trajectory of cancer care. Nat Rev Clin Oncol, 13(3), 159-171. doi:10.1038/nrclinonc.2015.201

Huo, Y. R., Chan, M. V., Habib, A. R., Lui, I., & Ridley, L. (2020). Pneumothorax rates in CT-Guided lung biopsies: a comprehensive systematic review and meta-analysis of risk factors. Br J Radiol, 93(1108), 20190866. doi:10.1259/bjr.20190866

Ignatius Ou, S. H., & Zell, J. A. (2009). The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC 6th TNM Edition. J Thorac Oncol, 4(3), 300-310. doi:10.1097/JTO.0b013e318194a355

Iyengar, P., Wardak, Z., Gerber, D. E., Tumati, V., Ahn, C., Hughes, R. S., . . . Timmerman, R. D. (2018). Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol, 4(1), e173501. doi:10.1001/jamaoncol.2017.3501

Iyoda, A., Hiroshima, K., Moriya, Y., Iwadate, Y., Takiguchi, Y., Uno, T., . . . Yoshino, I. (2009). Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma. J Thorac Cardiovasc Surg, 138(2), 446-453. doi:10.1016/j.jtcvs.2008.12.037

Jakopovic, M., Bitar, L., Seiwerth, F., Marusic, A., Krpina, K., & Samarzija, M. (2020). Immunotherapy for thymoma. J Thorac Dis, 12(12), 7635-7641. doi:10.21037/jtd-2019-thym-12

Jasper, K., Stiles, B., McDonald, F., & Palma, D. A. (2022). Practical Management of Oligometastatic Non-Small-Cell Lung Cancer. J Clin Oncol, 40(6), 635-641. doi:10.1200/JCO.21.01719

Jennings, A. L., Davies, A. N., Higgins, J. P., Gibbs, J. S., & Broadley, K. E. (2002). A systematic review of the use of opioids in the management of dyspnoea. Thorax, 57(11), 939-944. doi:10.1136/thorax.57.11.939

Jensen, L. H., Osterlind, K., & Rytter, C. (2008). Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer, 62(1), 85-91.

Johnson, D. B., Chandra, S., & Sosman, J. A. (2018). Immune Checkpoint Inhibitor Toxicity in 2018. JAMA, 320(16), 1702-1703. doi:10.1001/jama.2018.13995

Johnson, M. L., De Langen, J., Waterhouse, D. M., Mazieres, J., Dingemans, A. C., Mountzios, G., . . . Paz-Ares  , L. (2022). Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study. Ann Oncol, 33, S808-S869.

Johnson, P. T., Horton, K. M., & Fishman, E. K. (2009). Adrenal mass imaging with multidetector CT: pathologic conditions, pearls, and pitfalls. Radiographics, 29(5), 1333-1351. doi:10.1148/rg.295095027

Kaasa, S., Loge, J. H., Aapro, M., Albreht, T., Anderson, R., Bruera, E., . . . Lundeby, T. (2018). Integration of oncology and palliative care: a Lancet Oncology Commission. Lancet Oncol, 19(11), e588-e653. doi:10.1016/S1470-2045(18)30415-7

Kadota, K., Suzuki, K., Colovos, C., Sima, C. S., Rusch, V. W., Travis, W. D., & Adusumilli, P. S. (2012). A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma. Mod Pathol, 25(2), 260-271. doi:10.1038/modpathol.2011.146

Kandathil, A., Kay, F. U., Butt, Y. M., Wachsmann, J. W., & Subramaniam, R. M. (2018). Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non-Small Cell Lung Cancer. Radiographics, 38(7), 2134-2149. doi:10.1148/rg.2018180060

Kandathil, A., & Subramaniam, R. M. (2022). FDG PET/CT for Primary Staging of Lung Cancer and Mesothelioma. Semin Nucl Med, 52(6), 650-661. doi:10.1053/j.semnuclmed.2022.04.011

Kann, B. H., Miccio, J. A., Stahl, J. M., Ross, R., Verma, V., Dosoretz, A. P., . . . Decker, R. H. (2019). Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis. Radiother Oncol, 132, 188-196. doi:10.1016/j.radonc.2018.10.017

Kantor, T., & Wakeam, E. (2021). Landmark Trials in the Surgical Management of Mesothelioma. Ann Surg Oncol. doi:10.1245/s10434-021-09589-5

Kauczor, H. U., Bonomo, L., Gaga, M., Nackaerts, K., Peled, N., Prokop, M., . . . (ERS), E. R. S. (2015). ESR/ERS white paper on lung cancer screening. Eur Respir J, 46(1), 28-39. doi:10.1183/09031936.00033015

Kelly, R. J., Sharon, E., & Hassan, R. (2011). Chemotherapy and targeted therapies for unresectable malignant mesothelioma. Lung Cancer, 73(3), 256-263. doi:10.1016/j.lungcan.2011.04.014

Kenmotsu, H., Yamamoto, N., Yamanaka, T., Yoshiya, K., Takahashi, T., Ueno, T., . . . Tsuboi, M. (2020). Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol, 38(19), 2187-2196. doi:10.1200/JCO.19.02674

Kennedy, L. C., Bhatia, S., Thompson, J. A., & Grivas, P. (2019). Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors. J Natl Compr Canc Netw, 17(6), 750-757. doi:10.6004/jnccn.2019.7310

Kidane, B., Bott, M., Spicer, J., Backhus, L., Chaft, J., Chudgar, N., . . . Stiles, B. (2023). The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and multidisciplinary management of patients with early-stage non-small cell lung cancer. J Thorac Cardiovasc Surg, 166(3), 637-654. doi:10.1016/j.jtcvs.2023.04.039

Kim, D. W., Tiseo, M., Ahn, M. J., Reckamp, K. L., Hansen, K. H., Kim, S. W., . . . Camidge, D. R. (2017). Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. J Clin Oncol, 35(22), 2490-2498. doi:10.1200/JCO.2016.71.5904

Kim, M., Suh, C. H., Lee, S. M., Kim, H. C., Aizer, A. A., Yanagihara, T. K., . . . Kim, H. S. (2020). Diagnostic Yield of Staging Brain MRI in Patients with Newly Diagnosed Non-Small Cell Lung Cancer. Radiology, 297(2), 419-427. doi:10.1148/radiol.2020201194

Kodama, K., Doi, O., Higashiyama, M., & Yokouchi, H. (1997). Intentional limited resection for selected patients with T1 N0 M0 non-small-cell lung cancer: a single-institution study. J Thorac Cardiovasc Surg, 114(3), 347-353.

Komaki, R., & Gomez, D. R. (2014). Radiotherapy for Thymic Carcinoma: Adjuvant, Inductive, and Definitive. Front Oncol, 3, 330. doi:10.3389/fonc.2013.00330

Komiya, T., Ravindra, N., & Powell, E. (2021). Role of Immunotherapy in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung. Asian Pac J Cancer Prev, 22(2), 365-370. doi:10.31557/APJCP.2021.22.2.365

Korse, C. M., Taal, B. G., Vincent, A., van Velthuysen, M. L., Baas, P., Buning-Kager, J. C., . . . Bonfrer, J. M. (2012). Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments. Eur J Cancer, 48(5), 662-671. doi:10.1016/j.ejca.2011.08.012

Korst, R. J., Bezjak, A., Blackmon, S., Choi, N., Fidias, P., Liu, G., . . . Keshavjee, S. (2014). Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: a phase II, multi-institutional clinical trial. J Thorac Cardiovasc Surg, 147(1), 36-44, 46.e31. doi:10.1016/j.jtcvs.2013.08.061

Kozower, B. D., Larner, J. M., Detterbeck, F. C., & Jones, D. R. (2013). Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 143(5 Suppl), e369S-e399S. doi:10.1378/chest.12-2362

Kreuter, M., Vansteenkiste, J., Fischer, J. R., Eberhardt, W., Zabeck, H., Kollmeier, J., . . . investigators, T. (2013). Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. Ann Oncol, 24(4), 986-992. doi:10.1093/annonc/mds578

Krug, L. M., Pass, H. I., Rusch, V. W., Kindler, H. L., Sugarbaker, D. J., Rosenzweig, K. E., . . . Vogelzang, N. J. (2009). Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol, 27(18), 3007-3013. doi:10.1200/JCO.2008.20.3943

Kulke, M. H., Lenz, H. J., Meropol, N. J., Posey, J., Ryan, D. P., Picus, J., . . . Fuchs, C. S. (2008). Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol, 26(20), 3403-3410. doi:10.1200/JCO.2007.15.9020

Kumar, A., Weber, M. H., Gokaslan, Z., Wolinsky, J. P., Schmidt, M., Rhines, L., . . . Fisher, C. G. (2017). Metastatic Spinal Cord Compression and Steroid Treatment: A Systematic Review. Clin Spine Surg, 30(4), 156-163. doi:10.1097/BSD.0000000000000528

Lababede, O., & Meziane, M. A. (2018). The Eighth Edition of TNM Staging of Lung Cancer: Reference Chart and Diagrams. Oncologist, 23(7), 844-848. doi:10.1634/theoncologist.2017-0659

Lad, T., Piantadosi, S., Thomas, P., Payne, D., Ruckdeschel, J., & Giaccone, G. (1994). A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest, 106(6 Suppl), 320S-323S.

Lakha, S., Gomez, J. E., Flores, R. M., & Wisnivesky, J. P. (2014). Prognostic significance of visceral pleural involvement in early-stage lung cancer. Chest, 146(6), 1619-1626. doi:10.1378/chest.14-0204

Lamba, N., Muskens, I. S., DiRisio, A. C., Meijer, L., Briceno, V., Edrees, H., . . . Broekman, M. L. (2017). Stereotactic radiosurgery versus whole-brain radiotherapy after intracranial metastasis resection: a systematic review and meta-analysis. Radiat Oncol, 12(1), 106. doi:10.1186/s13014-017-0840-x

Larici, A. R., Franchi, P., Del Ciello, A., Sica, G., Coviello, D., De Waure, C., . . . Manfredi, R. (2021). Role of delayed phase contrast-enhanced CT in the intra-thoracic staging of non-small cell lung cancer (NSCLC): What does it add? Eur J Radiol, 144, 109983. doi:10.1016/j.ejrad.2021.109983

Le Pechoux, C., Pourel, N., Barlesi, F., Lerouge, D., Antoni, D., Lamezec, B., . . . Bardet, A. (2022). Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial. Lancet Oncol, 23(1), 104-114. doi:10.1016/S1470-2045(21)00606-9

Le Péchoux, C., Dunant, A., Senan, S., Wolfson, A., Quoix, E., Faivre-Finn, C., . . . Group, P. C. I. P. C. (2009). Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol, 10(5), 467-474. doi:10.1016/S1470-2045(09)70101-9

Le Péchoux, C., Laplanche, A., Faivre-Finn, C., Ciuleanu, T., Wanders, R., Lerouge, D., . . . Group, P. C. I. P. C. (2011). Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). Ann Oncol, 22(5), 1154-1163. doi:10.1093/annonc/mdq576

Le Treut, J., Sault, M. C., Lena, H., Souquet, P. J., Vergnenegre, A., Le Caer, H., . . . Chouaid, C. (2013). Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. Ann Oncol, 24(6), 1548-1552. doi:10.1093/annonc/mdt009

Lee, T. H., Marcantonio, E. R., Mangione, C. M., Thomas, E. J., Polanczyk, C. A., Cook, E. F., . . . Goldman, L. (1999). Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation, 100(10), 1043-1049.

Lemaire, A., Nikolic, I., Petersen, T., Haney, J. C., Toloza, E. M., Harpole, D. H., Jr., . . . Burfeind, W. R. (2006). Nine-year single center experience with cervical mediastinoscopy: complications and false negative rate. Ann Thorac Surg, 82(4), 1185-1189; discussion 1189-1190. doi:10.1016/j.athoracsur.2006.05.023

Leonardi, G. C., Gainor, J. F., Altan, M., Kravets, S., Dahlberg, S. E., Gedmintas, L., . . . Awad, M. M. (2018). Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. J Clin Oncol, 36(19), 1905-1912. doi:10.1200/JCO.2017.77.0305

Leong, T. L., Loveland, P. M., Gorelik, A., Irving, L., & Steinfort, D. P. (2019). Preoperative Staging by EBUS in cN0/N1 Lung Cancer: Systematic Review and Meta-Analysis. J Bronchology Interv Pulmonol, 26(3), 155-165. doi:10.1097/LBR.0000000000000545

Li, A., Garcia, D. A., Lyman, G. H., & Carrier, M. (2019). Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. Thromb Res, 173, 158-163. doi:10.1016/j.thromres.2018.02.144

Li, X., & Kong, L. (2023). Ultrasound versus computed tomography-guided transthoracic biopsy for pleural and peripheral lung lesions: a systematic review and meta-analysis. Acta Radiol, 64(12), 2999-3008. doi:10.1177/02841851231206349

Li, Y., Chen, W., Xie, F., Huang, R., Liu, X., Xiao, Y., . . . Sun, J. (2023). Novel electromagnetic navigation bronchoscopy system for the diagnosis of peripheral pulmonary nodules: a prospective, multicentre study. Thorax, 78(12), 1197-1205. doi:10.1136/thorax-2022-219664

Li, Y., Yang, F., Huang, Y. Y., & Cao, W. (2022). Comparison between computed tomography-guided core and fine needle lung biopsy: A meta-analysis. Medicine (Baltimore), 101(9), e29016. doi:10.1097/MD.0000000000029016

Liao, X., Liu, M., Li, S., Huang, W., Guo, C., Liu, J., . . . Wang, R. (2023). The value on SUV-derived parameters assessed on (18)F-FDG PET/CT for predicting mediastinal lymph node metastasis in non-small cell lung cancer. BMC Med Imaging, 23(1), 49. doi:10.1186/s12880-023-01004-7

Liao, Z., Lee, J. J., Komaki, R., Gomez, D. R., O'Reilly, M. S., Fossella, F. V., . . . Mohan, R. (2018). Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol, 36(18), 1813-1822. doi:10.1200/JCO.2017.74.0720

Lim, E., Baldwin, D., Beckles, M., Duffy, J., Entwisle, J., Faivre-Finn, C., . . . Ireland, S. f. C. S. i. G. B. a. (2010). Guidelines on the radical management of patients with lung cancer. Thorax, 65 Suppl 3, iii1-27. doi:10.1136/thx.2010.145938

Lim, S. M., Kim, H. R., Lee, J. S., Lee, K. H., Lee, Y. G., Min, Y. J., . . . Cho, B. C. (2017). Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. J Clin Oncol, 35(23), 2613-2618. doi:10.1200/JCO.2016.71.3701

Limonnik, V., Abel, S., Finley, G. G., Long, G. S., & Wegner, R. E. (2020). Factors associated with treatment receipt and overall survival for patients with locally advanced large cell neuroendocrine carcinoma of the lung: A National Cancer Database analysis. Lung Cancer, 150, 107-113. doi:10.1016/j.lungcan.2020.10.001

Lindberg, K., Grozman, V., Karlsson, K., Lindberg, S., Lax, I., Wersäll, P., . . . Lewensohn, R. (2021). The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy. J Thorac Oncol, 16(7), 1200-1210. doi:10.1016/j.jtho.2021.03.019

Lisberg, A., Cummings, A., Goldman, J. W., Bornazyan, K., Reese, N., Wang, T., . . . Garon, E. B. (2018). A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC. J Thorac Oncol, 13(8), 1138-1145. doi:10.1016/j.jtho.2018.03.035

Lock, M. I., Hoyer, M., Bydder, S. A., Okunieff, P., Hahn, C. A., Vichare, A., & Dawson, L. A. (2012). An international survey on liver metastases radiotherapy. Acta Oncol, 51(5), 568-574. doi:10.3109/0284186X.2012.681700

Lococo, F., Guerrera, F., Rena, O., Ampollini, L., Vannucci, J., Bertoglio, P., . . . Ruffini, E. (2022). Accuracy of (18)F-FDG in Detecting Stage I Lung Adenocarcinomas According to IASLC/ATS/ERS Classification. Heart Lung Circ, 31(5), 726-732. doi:10.1016/j.hlc.2021.10.011

Loehrer, P. J., Wang, W., Johnson, D. H., Aisner, S. C., Ettinger, D. S., & Trial, E. C. O. G. P. I. (2004). Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol, 22(2), 293-299. doi:10.1200/JCO.2004.02.047

Lou, F., Huang, J., Sima, C. S., Dycoco, J., Rusch, V., & Bach, P. B. (2013). Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. J Thorac Cardiovasc Surg, 145(1), 75-81; discussion 81-72. doi:10.1016/j.jtcvs.2012.09.030

Loulergue, P., Alexandre, J., Iurisci, I., Grabar, S., Medioni, J., Ropert, S., . . . Launay, O. (2011). Low immunogenicity of seasonal trivalent influenza vaccine among patients receiving docetaxel for a solid tumour: results of a prospective pilot study. Br J Cancer, 104(11), 1670-1674. doi:10.1038/bjc.2011.142

Louw, A., Panou, V., Szejniuk, W. M., Meristoudis, C., Chai, S. M., van Vliet, C., . . . Røe, O. D. (2022). BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study. J Thorac Oncol, 17(7), 921-930. doi:10.1016/j.jtho.2022.04.008

Lund-Iversen, M., Grøholt, K. K., Helland, Å., Borgen, E., & Brustugun, O. T. (2015). NUT expression in primary lung tumours. Diagn Pathol, 10, 156. doi:10.1186/s13000-015-0395-9

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., . . . Haber, D. A. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350(21), 2129-2139.

Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., . . . Group, E. S. D. (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J, 43(41), 4229-4361. doi:10.1093/eurheartj/ehac244

Mackley, H. B., & Videtic, G. M. (2006). Primary carcinoid tumors of the lung: a role for radiotherapy. Oncology (Williston Park), 20(12), 1537-1543; discussion 1544-1535, 1549.

MacMahon, H., Naidich, D. P., Goo, J. M., Lee, K. S., Leung, A. N. C., Mayo, J. R., . . . Bankier, A. A. (2017). Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology, 284(1), 228-243. doi:10.1148/radiol.2017161659

Manohar, S., Thongprayoon, C., Cheungpasitporn, W., Markovic, S. N., & Herrmann, S. M. (2020). Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients. Kidney Int Rep, 5(2), 149-158. doi:10.1016/j.ekir.2019.11.015

Mao, J., Kocak, Z., Zhou, S., Garst, J., Evans, E. S., Zhang, J., . . . Marks, L. B. (2007). The impact of induction chemotherapy and the associated tumor response on subsequent radiation-related changes in lung function and tumor response. Int J Radiat Oncol Biol Phys, 67(5), 1360-1369. doi:10.1016/j.ijrobp.2006.11.003

Marinaccio, A., Binazzi, A., Cauzillo, G., Cavone, D., Zotti, R. D., Ferrante, P., . . . Tumino, R. (2007). Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. Eur J Cancer, 43(18), 2722-2728. doi:S0959-8049(07)00748-4 [pii] 10.1016/j.ejca.2007.09.018

Marom, E. M. (2013). Advances in thymoma imaging. J Thorac Imaging, 28(2), 69-80; quiz 81-63. doi:10.1097/RTI.0b013e31828609a0

Martinez-Zayas, G., Molina, S., & Ost, D. E. (2022). Sensitivity and complications of thoracentesis and thoracoscopy: a meta-analysis. Eur Respir Rev, 31(166). doi:10.1183/16000617.0053-2022

Martinou, M., & Gaya, A. (2013). Cardiac complications after radical radiotherapy. Semin Oncol, 40(2), 178-185. doi:10.1053/j.seminoncol.2013.01.007

Marx, A., Chan, J. K. C., Chalabreysse, L., Dacic, S., Detterbeck, F., French, C. A., . . . Ströbel, P. (2022). The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors? J Thorac Oncol, 17(2), 200-213. doi:10.1016/j.jtho.2021.10.010

Masaoka, A. (2010). Staging system of thymoma. J Thorac Oncol, 5(10 Suppl 4), S304-312. doi:10.1097/JTO.0b013e3181f20c05

Massoth, L. R., Hung, Y. P., Dias-Santagata, D., Onozato, M., Shah, N., Severson, E., . . . Williams, E. A. (2020). Pan-Cancer Landscape Analysis Reveals Recurrent KMT2A- MAML2 Gene Fusion in Aggressive Histologic Subtypes of Thymoma. JCO Precis Oncol, 4. doi:10.1200/PO.19.00288

Matheos, T., Ram, L., & Canelli, R. (2020). Preoperative Evaluation for Thoracic Surgery. Thorac Surg Clin, 30(3), 241-247. doi:10.1016/j.thorsurg.2020.04.003

Matsumoto, R., Takamori, S., Yokoyama, S., Hashiguchi, T., Murakami, D., Yoshiyama, K., . . . Akagi, Y. (2018). Lung function in the late postoperative phase and influencing factors in patients undergoing pulmonary lobectomy. J Thorac Dis, 10(5), 2916-2923. doi:10.21037/jtd.2018.05.27

McKenna, R. J., Mahtabifard, A., Yap, J., McKenna, R., Fuller, C., Merhadi, A., & Hakimian, B. (2008). Wedge resection and brachytherapy for lung cancer in patients with poor pulmonary function. Ann Thorac Surg, 85(2), 733-736.

Mehrotra, M., D'Cruz, J. R., & Arthur, M. E. (2023). Video-Assisted Thoracoscopy. In StatPearls. Treasure Island (FL).

Mehta, V. (2005). Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys, 63(1), 5-24. doi:10.1016/j.ijrobp.2005.03.047

Mesko, S., & Gomez, D. (2018). Proton Therapy in Non-small Cell Lung Cancer. Curr Treat Options Oncol, 19(12), 76. doi:10.1007/s11864-018-0588-z

Moertel, C. G., & Hanley, J. A. (1979). Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials, 2(4), 327-334.

Moertel, C. G., Kvols, L. K., O'Connell, M. J., & Rubin, J. (1991). Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer, 68(2), 227-232.

Mok, T. S., Wu, Y. L., Ahn, M. J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., . . . Investigators, A. (2017). Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med, 376(7), 629-640. doi:10.1056/NEJMoa1612674

Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saijo, N., . . . Fukuoka, M. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361(10), 947-957.

Mok, T. S. K., Wu, Y. L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., . . . Investigators, K.-. (2019). Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, 393(10183), 1819-1830. doi:10.1016/S0140-6736(18)32409-7

Mollberg, N. M., & Ferguson, M. K. (2013). Postoperative surveillance for non-small cell lung cancer resected with curative intent: developing a patient-centered approach. Ann Thorac Surg, 95(3), 1112-1121. doi:10.1016/j.athoracsur.2012.09.075

Mulvenna, P., Nankivell, M., Barton, R., Faivre-Finn, C., Wilson, P., McColl, E., . . . Langley, R. E. (2016). Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet, 388(10055), 2004-2014. doi:10.1016/S0140-6736(16)30825-X

Mynarek, G. K., & Bosse, G. (2016). [Not Available]. Tidsskr Nor Laegeforen, 136(16), 1323-1324. doi:10.4045/tidsskr.16.0684

Naidoo, J., Santos-Zabala, M. L., Iyriboz, T., Woo, K. M., Sima, C. S., Fiore, J. J., . . . Pietanza, M. C. (2016). Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. Clin Lung Cancer, 17(5), e121-e129. doi:10.1016/j.cllc.2016.01.003

Nakamura, K., Matsumoto, K., Inoue, C., Matsusue, E., & Fujii, S. (2021). Computed Tomography-guided Lung Biopsy: A Review of Techniques for Reducing the Incidence of Complications. Interv Radiol (Higashimatsuyama), 6(3), 83-92. doi:10.22575/interventionalradiology.2021-0012

Nantavithya, C., Gomez, D. R., Wei, X., Komaki, R., Liao, Z., Lin, S. H., . . . Chang, J. Y. (2018). Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys, 101(3), 558-563. doi:10.1016/j.ijrobp.2018.02.022

Neyman, K., Sundset, A., Naalsund, A., Espinoza, A., Solberg, S., Kongerud, J., & Fosse, E. (2012). Endoscopic treatment of bronchial carcinoids in comparison to surgical resection: a retrospective study. J Bronchology Interv Pulmonol, 19(1), 29-34. doi:10.1097/LBR.0b013e3182446b52

Nezu, K., Kushibe, K., Tojo, T., Takahama, M., & Kitamura, S. (1998). Recovery and limitation of exercise capacity after lung resection for lung cancer. Chest, 113(6), 1511-1516.

Ng, T. L., Narasimhan, N., Gupta, N., Venkatakrishnan, K., Kerstein, D., & Camidge, D. R. (2020). Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced NSCLC. J Thorac Oncol, 15(7), 1190-1199. doi:10.1016/j.jtho.2020.02.011

Nguyen, Q. N., Chun, S. G., Chow, E., Komaki, R., Liao, Z., Zacharia, R., . . . Lewis, V. O. (2019). Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Trial. JAMA Oncol. doi:10.1001/jamaoncol.2019.0192

Noonan, C. W. (2017). Environmental asbestos exposure and risk of mesothelioma. Ann Transl Med, 5(11), 234. doi:10.21037/atm.2017.03.74

Nussbaum, D. P., Speicher, P. J., Gulack, B. C., Hartwig, M. G., Onaitis, M. W., D'Amico, T. A., & Berry, M. F. (2015). Defining the role of adjuvant chemotherapy after lobectomy for typical bronchopulmonary carcinoid tumors. Ann Thorac Surg, 99(2), 428-434. doi:10.1016/j.athoracsur.2014.08.030

O'Brien, M. E., Ciuleanu, T. E., Tsekov, H., Shparyk, Y., Cuceviá, B., Juhasz, G., . . . Crofts, T. (2006). Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol, 24(34), 5441-5447. doi:10.1200/JCO.2006.06.5821

O'Brien, M. E., Watkins, D., Ryan, C., Priest, K., Corbishley, C., Norton, A., . . . Sayer, R. (2006). A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol, 17(2), 270-275. doi:10.1093/annonc/mdj073

O'Rourke, N., Garcia, J. C., Paul, J., Lawless, C., McMenemin, R., & Hill, J. (2007). A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol, 84(1), 18-22.

Oken, M. M., Hocking, W. G., Kvale, P. A., Andriole, G. L., Buys, S. S., Church, T. R., . . . Team, P. P. (2011). Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA, 306(17), 1865-1873. doi:10.1001/jama.2011.1591

Ostios-Garcia, L., Faig, J., Leonardi, G. C., Adeni, A. E., Subegdjo, S. J., Lydon, C. A., . . . Awad, M. M. (2018). Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer. J Thorac Oncol, 13(7), 1037-1042. doi:10.1016/j.jtho.2018.03.031

Ou, S. H., Ahn, J. S., De Petris, L., Govindan, R., Yang, J. C., Hughes, B., . . . Kim, D. W. (2016). Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. J Clin Oncol, 34(7), 661-668. doi:10.1200/jco.2015.63.9443

Ou, S. I., Nishio, M., Ahn, M. J., Mok, T., Barlesi, F., Zhou, C., . . . Kim, E. S. (2022). Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2). J Thorac Oncol. doi:10.1016/j.jtho.2022.08.018

Owen, D. H., Benner, B., Wei, L., Sukrithan, V., Goyal, A., Zhou, Y., . . . Konda, B. (2022). A phase 2 clinical trial of nivolumab and temozolomide for neuroendocrine neoplasms. Clin Cancer Res. doi:10.1158/1078-0432.CCR-22-1552

Owens, C., Hindocha, S., Lee, R., Millard, T., & Sharma, B. (2023). The lung cancers: staging and response, CT, (18)F-FDG PET/CT, MRI, DWI: review and new perspectives. Br J Radiol, 96(1148), 20220339. doi:10.1259/bjr.20220339

Padda, S. K., Riess, J. W., Schwartz, E. J., Tian, L., Kohrt, H. E., Neal, J. W., . . . Wakelee, H. A. (2015). Diffuse high intensity PD-L1 staining in thymic epithelial tumors. J Thorac Oncol, 10(3), 500-508. doi:10.1097/JTO.0000000000000429

Page, S., Milner-Watts, C., Perna, M., Janzic, U., Vidal, N., Kaudeer, N., . . . O'Brien, M. (2020). Systemic treatment of brain metastases in non-small cell lung cancer. Eur J Cancer, 132, 187-198. doi:10.1016/j.ejca.2020.03.006

Paik, P. K., Felip, E., Veillon, R., Sakai, H., Cortot, A. B., Garassino, M. C., . . . Le, X. (2020). Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med, 383(10), 931-943. doi:10.1056/NEJMoa2004407

Palussière, J., Cazayus, M., Cousin, S., Cabart, M., Chomy, F., Catena, V., & Buy, X. (2021). Is There a Role for Percutaneous Ablation for Early Stage Lung Cancer? What Is the Evidence? Curr Oncol Rep, 23(7), 81. doi:10.1007/s11912-021-01072-4

Pancoast, H. (1932). Superior pulmonary sulcus tumor. JAMA, 99, 1391-1396.

Park, K., Haura, E. B., Leighl, N. B., Mitchell, P., Shu, C. A., Girard, N., . . . Cho, B. C. (2021). Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol, 39(30), 3391-3402. doi:10.1200/JCO.21.00662

Patchell, R. A., Tibbs, P. A., Regine, W. F., Payne, R., Saris, S., Kryscio, R. J., . . . Young, B. (2005). Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet, 366(9486), 643-648.

Patel, A., Roshkovan, L., McNulty, S., Alley, E., Torigian, D. A., Nachiappan, A. C., . . . Katz, S. I. (2021). Delayed-Phase Enhancement for Evaluation of Malignant Pleural Mesothelioma on Computed Tomography: A Prospective Cohort Study. Clin Lung Cancer, 22(3), 210-217.e211. doi:10.1016/j.cllc.2020.06.002

Patel, N. V., Yu, N. Y., Koroulakis, A., Diwanji, T., Sawant, A., Sio, T. T., & Mohindra, P. (2021). Proton therapy for thoracic malignancies: a review of oncologic outcomes. Expert Rev Anticancer Ther, 21(2), 177-191. doi:10.1080/14737140.2021.1844567

Patel, S. H., Robbins, J. R., Gore, E. M., Bradley, J. D., Gaspar, L. E., Germano, I., . . . Metastases, E. P. o. R. O. B. (2012). ACR Appropriateness Criteria® follow-up and retreatment of brain metastases. Am J Clin Oncol, 35(3), 302-306. doi:10.1097/COC.0b013e31824be246

Payne, C., Larkin, P. J., McIlfatrick, S., Dunwoody, L., & Gracey, J. H. (2013). Exercise and nutrition interventions in advanced lung cancer: a systematic review. Curr Oncol, 20(4), e321-337. doi:10.3747/co.20.1431

Paz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., . . . investigators, C. (2019). Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet, 394(10212), 1929-1939. doi:10.1016/S0140-6736(19)32222-6

Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., . . . Investigators, K.-. (2018). Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med, 379(21), 2040-2051. doi:10.1056/NEJMoa1810865

Paz-Ares, L., Vicente, D., Tafreshi, A., Robinson, A., Soto Parra, H., Mazières, J., . . . Halmos, B. (2020). A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. J Thorac Oncol, 15(10), 1657-1669. doi:10.1016/j.jtho.2020.06.015

Pedersen, J. H., Sørensen, J. B., Saghir, Z., Fløtten, Ø., Brustugun, O. T., Ashraf, H., . . . Gudbjartsson, T. (2017). Implementation of lung cancer CT screening in the Nordic countries. Acta Oncol, 56(10), 1249-1257. doi:10.1080/0284186X.2017.1329592

Pelayo Alvarez, M., Gallego Rubio, O., Bonfill Cosp, X., & Agra Varela, Y. (2009). Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev(4), CD001990. doi:10.1002/14651858.CD001990.pub2

Pencharz, D., Modi, S., Bandyopadhyay, S., Alhun, U., Marchbank, N., Patel, A., & Wagner, T. (2022). Absence of clinical benefit of FDG PET-CT in staging T1 part-solid lung adenocarcinoma. Clin Radiol, 77(3), 195-202. doi:10.1016/j.crad.2021.11.013

Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D. W., . . . Investigators, A. T. (2017). Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. doi:10.1056/NEJMoa1704795

Pignon, J. P., Tribodet, H., Scagliotti, G. V., Douillard, J. Y., Shepherd, F. A., Stephens, R. J., . . . Group, L. C. (2008). Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol, 26(21), 3552-3559. doi:10.1200/JCO.2007.13.9030

Pijls-Johannesma, M. C. G., De Ruysscher, D., Lambin, P., Rutten, I., & Vansteenkiste, J. F. (2005). Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev(1).

Planchard, D., Besse, B., Groen, H. J., Souquet, P. J., Quoix, E., Baik, C. S., . . . Johnson, B. E. (2016). Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol, 17(7), 984-993. doi:10.1016/S1470-2045(16)30146-2

Planchard, D., Besse, B., Groen, H. J. M., Hashemi, S. M. S., Mazieres, J., Kim, T. M., . . . Johnson, B. E. (2022). Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis. J Thorac Oncol, 17(1), 103-115. doi:10.1016/j.jtho.2021.08.011

Planchard, D., Smit, E. F., Groen, H. J. M., Mazieres, J., Besse, B., Helland, Å., . . . Johnson, B. E. (2017). Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol, 18(10), 1307-1316. doi:10.1016/S1470-2045(17)30679-4

Polanski, J., Jankowska-Polanska, B., Rosinczuk, J., Chabowski, M., & Szymanska-Chabowska, A. (2016). Quality of life of patients with lung cancer. Onco Targets Ther, 9, 1023-1028. doi:10.2147/OTT.S100685

Postmus, P. E., Kerr, K. M., Oudkerk, M., Senan, S., Waller, D. A., Vansteenkiste, J., . . . Committee, E. G. (2017). Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 28(suppl_4), iv1-iv21. doi:10.1093/annonc/mdx222

Prelaj, A., Pircher, C. C., Massa, G., Martelli, V., Corrao, G., Lo Russo, G., . . . Rebuzzi, S. E. (2021). Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression. Cancers (Basel), 13(6). doi:10.3390/cancers13061300

Prosperi, D., Carideo, L., Russo, V. M., Meucci, R., Campagna, G., Lastoria, S., & Signore, A. (2023). A Systematic Review on Combined [(18)F]FDG and (68)Ga-SSA PET/CT in Pulmonary Carcinoid. J Clin Med, 12(11). doi:10.3390/jcm12113719

Pujol, J. L., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Uwer, L., Hureaux, J., . . . Souquet, P. J. (2019). A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial. J Thorac Oncol, 14(5), 903-913. doi:10.1016/j.jtho.2019.01.008

Radovich, M., Pickering, C. R., Felau, I., Ha, G., Zhang, H., Jo, H., . . . Network, C. G. A. (2018). The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell, 33(2), 244-258.e210. doi:10.1016/j.ccell.2018.01.003

Rajan, A., Carter, C. A., Berman, A., Cao, L., Kelly, R. J., Thomas, A., . . . Giaccone, G. (2014). Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol, 15(2), 191-200. doi:10.1016/S1470-2045(13)70596-5

Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., . . . Investigators, F. (2020). Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med, 382(1), 41-50. doi:10.1056/NEJMoa1913662

Raman, V., Jawitz, O. K., Yang, C. J., Tong, B. C., D'Amico, T. A., Berry, M. F., & Harpole, D. H. (2019). Adjuvant Therapy for Patients With Early Large Cell Lung Neuroendocrine Cancer: A National Analysis. Ann Thorac Surg, 108(2), 377-383. doi:10.1016/j.athoracsur.2019.03.053

Raman, V., Jawitz, O. K., Yang, C. J., Voigt, S. L., Tong, B. C., D'Amico, T. A., & Harpole, D. H. (2019). Outcomes for Surgery in Large Cell Lung Neuroendocrine Cancer. J Thorac Oncol, 14(12), 2143-2151. doi:10.1016/j.jtho.2019.09.005

Reck, M., Popat, S., Reinmuth, N., De Ruysscher, D., Kerr, K. M., Peters, S., & Group, E. G. W. (2014). Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 25 Suppl 3, iii27-39. doi:10.1093/annonc/mdu199

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., . . . Investigators, K.-. (2016). Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med, 375(19), 1823-1833. doi:10.1056/NEJMoa1606774

Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., . . . Group, B. S. (2010). Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol, 21(9), 1804-1809. doi:10.1093/annonc/mdq020

Refai, M., Brunelli, A., Salati, M., Pompili, C., Xiumè, F., & Sabbatini, A. (2011). Efficacy of anterior fissureless technique for right upper lobectomies: a case-matched analysis. Eur J Cardiothorac Surg, 39(6), 1043-1046. doi:10.1016/j.ejcts.2010.09.039

Rekhtman, N. (2010). Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med, 134(11), 1628-1638. doi:10.5858/2009-0583-RAR.1

Rekhtman, N., Desmeules, P., Litvak, A. M., Pietanza, M. C., Santos-Zabala, M. L., Ni, A., . . . Lai, W. C. (2019). Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices. Mod Pathol, 32(8), 1106-1122. doi:10.1038/s41379-019-0248-2

Reveiz, L., Rueda, J. R., & Cardona, A. F. (2012). Palliative endobronchial brachytherapy for non-small cell lung cancer. Cochrane Database Syst Rev, 12, CD004284. doi:10.1002/14651858.CD004284.pub3

Rheinheimer, S., Heussel, C. P., Mayer, P., Gaissmaier, L., Bozorgmehr, F., Winter, H., . . . Christopoulos, P. (2020). Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors. Cancers (Basel), 12(4). doi:10.3390/cancers12041046

Ricciuti, B., Dahlberg, S. E., Adeni, A., Sholl, L. M., Nishino, M., & Awad, M. M. (2019). Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. J Clin Oncol, JCO1900189. doi:10.1200/JCO.19.00189

Rieber, J., Schmitt, J., Warth, A., Muley, T., Kappes, J., Eichhorn, F., . . . Rieken, S. (2015). Outcome and prognostic factors of multimodal therapy for pulmonary large-cell neuroendocrine carcinomas. Eur J Med Res, 20, 64. doi:10.1186/s40001-015-0158-9

Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., . . . Group, O. S. (2017). Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet, 389(10066), 255-265. doi:10.1016/S0140-6736(16)32517-X

Rivera, M. P., Mehta, A. C., & Wahidi, M. M. (2013). Establishing the Diagnosis of Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 143(5 Suppl), e142S-165S. doi:10.1378/chest.12-2353

Rogasch, J. M. M., Frost, N., Bluemel, S., Michaels, L., Penzkofer, T., von Laffert, M., . . . Furth, C. (2021). FDG-PET/CT for pretherapeutic lymph node staging in non-small cell lung cancer: A tailored approach to the ESTS/ESMO guideline workflow. Lung Cancer, 157, 66-74. doi:10.1016/j.lungcan.2021.05.003

Rogasch, J. M. M., Hofheinz, F., van Heek, L., Voltin, C. A., Boellaard, R., & Kobe, C. (2022). Influences on PET Quantification and Interpretation. Diagnostics (Basel), 12(2). doi:10.3390/diagnostics12020451

Romi, F. (2011). Thymoma in myasthenia gravis: from diagnosis to treatment. Autoimmune Dis, 2011, 474512. doi:10.4061/2011/474512

Romi, F., Skeie, G. O., Aarli, J. A., & Gilhus, N. E. (2000). Muscle autoantibodies in subgroups of myasthenia gravis patients. J Neurol, 247(5), 369-375.

Ropper, A. E., & Ropper, A. H. (2017). Acute Spinal Cord Compression. N Engl J Med, 376(14), 1358-1369. doi:10.1056/NEJMra1516539

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., . . . Toracica, S. L. C. G. i. c. w. G. F. d. P.-C. a. A. I. O. (2012). Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 13(3), 239-246. doi:10.1016/S1470-2045(11)70393-X

Rosen, L. S., Gordon, D., Tchekmedyian, N. S., Yanagihara, R., Hirsh, V., Krzakowski, M., . . . Seaman, J. (2004). Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer, 100(12), 2613-2621. doi:10.1002/cncr.20308

Rosen, L. S., Gordon, D., Tchekmedyian, S., Yanagihara, R., Hirsh, V., Krzakowski, M., . . . Seaman, J. J. (2003). Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol, 21(16), 3150-3157. doi:10.1200/JCO.2003.04.105

Rossi, G., Cavazza, A., Marchioni, A., Longo, L., Migaldi, M., Sartori, G., . . . Brambilla, E. (2005). Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol, 23(34), 8774-8785. doi:10.1200/JCO.2005.02.8233

Rousseau, B., Loulergue, P., Mir, O., Krivine, A., Kotti, S., Viel, E., . . . Tournigand, C. (2012). Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study. Ann Oncol, 23(2), 450-457. doi:10.1093/annonc/mdr141

Rowell, N. P., & Gleeson, F. V. (2001). Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus. Cochrane Database Syst Rev(4), CD001316.

Rubin, L. G., Levin, M. J., Ljungman, P., Davies, E. G., Avery, R., Tomblyn, M., . . . America, I. D. S. o. (2014). 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis, 58(3), e44-100. doi:10.1093/cid/cit684

Rubins, J., Unger, M., Colice, G. L., & Physicians, A. C. o. C. (2007). Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition). Chest, 132(3 Suppl), 355S-367S. doi:10.1378/chest.07-1390

Rudin, C. M., Awad, M. M., Navarro, A., Gottfried, M., Peters, S., Csőszi, T., . . . Investigators, K.-. (2020). Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol, 38(21), 2369-2379. doi:10.1200/JCO.20.00793

Rudin, C. M., Ismaila, N., Hann, C. L., Malhotra, N., Movsas, B., Norris, K., . . . Giaccone, G. (2015). Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. J Clin Oncol, 33(34), 4106-4111. doi:10.1200/JCO.2015.63.7918

Ruffini, E., Detterbeck, F., Van Raemdonck, D., Rocco, G., Thomas, P., Weder, W., . . . Venuta, F. (2014). Thymic Carcinoma: A Cohort Study of Patients from the European Society of Thoracic Surgeons Database. J Thorac Oncol, 9, 541–548.

Rusch, V. W., Chansky, K., Kindler, H. L., Nowak, A. K., Pass, H. I., Rice, D. C., . . . IASLC Staging and Prognostic Factors Committee, a. b., and participating institutions. (2016). The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. J Thorac Oncol, 11(12), 2112-2119. doi:10.1016/j.jtho.2016.09.124

Rusch, V. W., Giroux, D. J., Kraut, M. J., Crowley, J., Hazuka, M., Winton, T., . . . Gandara, D. (2007). Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol, 25(3), 313-318.

Rusthoven, C. G., Yamamoto, M., Bernhardt, D., Smith, D. E., Gao, D., Serizawa, T., . . . Robin, T. P. (2020). Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases: The FIRE-SCLC Cohort Study. JAMA Oncol, 6(7), 1028-1037. doi:10.1001/jamaoncol.2020.1271

Sabari, J. K., Leonardi, G. C., Shu, C. A., Umeton, R., Montecalvo, J., Ni, A., . . . Drilon, A. (2018). PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol, 29(10), 2085-2091. doi:10.1093/annonc/mdy334

Sadikov, E., Bezjak, A., Yi, Q. L., Wells, W., Dawson, L., Millar, B. A., & Laperriere, N. (2007). Value of whole brain re-irradiation for brain metastases--single centre experience. Clin Oncol (R Coll Radiol), 19(7), 532-538. doi:10.1016/j.clon.2007.06.001

Sagerup, C. M., Småstuen, M., Johannesen, T. B., Helland, Å., & Brustugun, O. T. (2011). Sex-specific trends in lung cancer incidence and survival: a population study of 40,118 cases. Thorax, 66(4), 301-307. doi:thx.2010.151621 [pii]


Saghir, Z., Dirksen, A., Ashraf, H., Bach, K. S., Brodersen, J., Clementsen, P. F., . . . Pedersen, J. H. (2012). CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT. Thorax, 67(4), 296-301. doi:10.1136/thoraxjnl-2011-200736

Saji, H., Tsuboi, M., Matsubayashi, J., Miyajima, K., Shimada, Y., Imai, K., . . . Ikeda, N. (2010). Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy. Anticancer Drugs, 21(1), 89-93. doi:10.1097/CAD.0b013e328330fd79

Salati, M., & Brunelli, A. (2016). Risk Stratification in Lung Resection. Curr Surg Rep, 4(11), 37. doi:10.1007/s40137-016-0158-x

Salazar, M. C., Rosen, J. E., Wang, Z., Arnold, B. N., Thomas, D. C., Herbst, R. S., . . . Boffa, D. J. (2017). Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery. JAMA Oncol, 3(5), 610-619. doi:10.1001/jamaoncol.2016.5829

Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., . . . Johnson, D. H. (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med, 355(24), 2542-2550.

Santoro, A., O'Brien, M. E., Stahel, R. A., Nackaerts, K., Baas, P., Karthaus, M., . . . Manegold, C. (2008). Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol, 3(7), 756-763. doi:10.1097/JTO.0b013e31817c73d6

Saunders, Y., Ross, J. R., Broadley, K. E., Edmonds, P. M., & Patel, S. (Writers). (2004). Systematic review of bisphosphonates for hypercalcaemia of malignancy. In.

Scherpereel, A., Astoul, P., Baas, P., Berghmans, T., Clayson, H., de Vuyst, P., . . . Force, E. R. S. E. S. o. T. S. T. (2010). Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J, 35(3), 479-495. doi:10.1183/09031936.00063109

Schild, S. E., Sio, T. T., Daniels, T. B., Chun, S. G., & Rades, D. (2017). Prophylactic Cranial Irradiation for Extensive Small-Cell Lung Cancer. J Oncol Pract, 13(11), 732-738. doi:10.1200/JOP.2017.026765

Schindewolf, M., & Weitz, J. I. (2020). Broadening the Categories of Patients Eligible for Extended Venous Thromboembolism Treatment. Thromb Haemost, 120(1), 14-26. doi:10.1055/s-0039-3400302

Schmidt-Hansen, M., Baldwin, D. R., & Hasler, E. (2012). What is the most effective follow-up model for lung cancer patients? A systematic review. J Thorac Oncol, 7(5), 821-824. doi:10.1097/JTO.0b013e31824afc55

Schneider, B. J., Ismaila, N., Aerts, J., Chiles, C., Daly, M. E., Detterbeck, F. C., . . . Altorki, N. (2020). Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline. J Clin Oncol, 38(7), 753-766. doi:10.1200/JCO.19.02748

Schneider, B. J., Saxena, A., & Downey, R. J. (2011). Surgery for early-stage small cell lung cancer. J Natl Compr Canc Netw, 9(10), 1132-1139.

Schneider, J. (2006). Tumor markers in detection of lung cancer. Adv Clin Chem, 42, 1-41.

Schoenfeld, A. J., Arbour, K. C., Rizvi, H., Iqbal, A. N., Gadgeel, S. M., Girshman, J., . . . Hellmann, M. D. (2019). Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann Oncol, 30(5), 839-844. doi:10.1093/annonc/mdz077

Schoenmaekers, J. J. A. O., Dingemans, A. C., & Hendriks, L. E. L. (2018). Brain imaging in early stage non-small cell lung cancer: still a controversial topic? J Thorac Dis, 10(Suppl 18), S2168-S2171. doi:10.21037/jtd.2018.06.68

Schreiber, D., Rineer, J., Weedon, J., Vongtama, D., Wortham, A., Kim, A., . . . Rotman, M. (2010). Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated? Cancer, 116(5), 1350-1357. doi:10.1002/cncr.24853

Schreuder, A., Jacobs, C., Scholten, E. T., van Ginneken, B., Schaefer-Prokop, C. M., & Prokop, M. (2020). Typical CT Features of Intrapulmonary Lymph Nodes: A Review. Radiol Cardiothorac Imaging, 2(4), e190159. doi:10.1148/ryct.2020190159

Schultheiss, T. E. (2008). The radiation dose-response of the human spinal cord. Int J Radiat Oncol Biol Phys, 71(5), 1455-1459. doi:10.1016/j.ijrobp.2007.11.075

Schwartz, L. H., Gandras, E. J., Colangelo, S. M., Ercolani, M. C., & Panicek, D. M. (1999). Prevalence and importance of small hepatic lesions found at CT in patients with cancer. Radiology, 210(1), 71-74. doi:10.1148/radiology.210.1.r99ja0371

Sculier, J. P., Berghmans, T., Castaigne, C., Luce, S., Sotiriou, C., Vermylen, P., & Paesmans, M. (1998). Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. Lung Cancer, 19(2), 141-151.

Sechi, E., & Zekeridou, A. (2021). Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies. J Thorac Oncol, 16(3), 381-394. doi:10.1016/j.jtho.2020.11.005

Seol, H. Y., Kim, Y. S., & Kim, S. J. (2021). Predictive Value of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for Assessment of Occult Lymph Node Metastasis in Non-Small Cell Lung Cancer. Oncology, 99(2), 96-104. doi:10.1159/000509988

Sequist, L. V., Yang, J. C., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., . . . Schuler, M. (2013). Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol, 31(27), 3327-3334. doi:10.1200/JCO.2012.44.2806

Sezer, A., Kilickap, S., Gümüş, M., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., . . . Rietschel, P. (2021). Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet, 397(10274), 592-604. doi:10.1016/S0140-6736(21)00228-2

Shaw, A. T., Bauer, T. M., de Marinis, F., Felip, E., Goto, Y., Liu, G., . . . Investigators, C. T. (2020). First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. N Engl J Med, 383(21), 2018-2029. doi:10.1056/NEJMoa2027187

Shaw, A. T., Gandhi, L., Gadgeel, S., Riely, G. J., Cetnar, J., West, H., . . . investigators, s. (2016). Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol, 17(2), 234-242. doi:10.1016/S1470-2045(15)00488-X

Shaw, A. T., Ou, S. H., Bang, Y. J., Camidge, D. R., Solomon, B. J., Salgia, R., . . . Iafrate, A. J. (2014). Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med, 371(21), 1963-1971. doi:10.1056/NEJMoa1406766

Shaw, A. T., Solomon, B. J., Besse, B., Bauer, T. M., Lin, C. C., Soo, R. A., . . . Martini, J. F. (2019). Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. J Clin Oncol, 37(16), 1370-1379. doi:10.1200/JCO.18.02236

Shaw, A. T., Solomon, B. J., Chiari, R., Riely, G. J., Besse, B., Soo, R. A., . . . Ou, S. I. (2019). Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. doi:10.1016/S1470-2045(19)30655-2

Shaw, P., & Agarwal, R. (2004). Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev(1).

Shepherd, F. A., Dancey, J., Ramlau, R., Mattson, K., Gralla, R., O'Rourke, M., . . . Berille, J. (2000). Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 18(10), 2095-2103.

Silva, S. C., Wilson, C., & Woll, P. J. (2015). Bone-targeted agents in the treatment of lung cancer. Ther Adv Med Oncol, 7(4), 219-228. doi:10.1177/1758834015582178

Silvestri, G. A., Gonzalez, A. V., Jantz, M. A., Margolis, M. L., Gould, M. K., Tanoue, L. T., . . . Detterbeck, F. C. (2013). Methods for Staging Non-small Cell Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 143(5 Suppl), e211S-250S. doi:10.1378/chest.12-2355

Simon, G. R., Turrisi, A., & Physicians, A. C. o. C. (2007). Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest, 132(3 Suppl), 324S-339S. doi:10.1378/chest.07-1385

Simone, C. B. (2017). Thoracic Radiation Normal Tissue Injury. Semin Radiat Oncol, 27(4), 370-377. doi:10.1016/j.semradonc.2017.04.009

Singh, D., Chen, Y., Cummings, M. A., & Milano, M. T. (2019). Inoperable Pulmonary Carcinoid Tumors: Local Control Rates With Stereotactic Body Radiotherapy/Hypofractionated RT With Image-Guided Radiotherapy. Clin Lung Cancer, 20(3), e284-e290. doi:10.1016/j.cllc.2019.02.003

Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., . . . Govindan, R. (2021). Sotorasib for Lung Cancers with KRAS p.G12C Mutations. N Engl J Med, 384(25), 2371-2381. doi:10.1056/NEJMoa2103695

Skov, B. G., & Skov, T. (2017). Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx. Appl Immunohistochem Mol Morphol, 25(7), 453-459. doi:10.1097/PAI.0000000000000540

Slotman, B. J., van Tinteren, H., Praag, J. O., Knegjens, J. L., El Sharouni, S. Y., Hatton, M., . . . Senan, S. (2015). Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet, 385(9962), 36-42. doi:10.1016/S0140-6736(14)61085-0

Smilowitz, N. R., & Berger, J. S. (2020). Perioperative Cardiovascular Risk Assessment and Management for Noncardiac Surgery: A Review. JAMA, 324(3), 279-290. doi:10.1001/jama.2020.7840

Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., . . . Group, I. S. (2018). Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med, 378(24), 2288-2301. doi:10.1056/NEJMoa1716948

Solomon, B. J., Besse, B., Bauer, T. M., Felip, E., Soo, R. A., Camidge, D. R., . . . Shaw, A. T. (2018). Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol, 19(12), 1654-1667. doi:10.1016/S1470-2045(18)30649-1

Solomon, B. J., Mok, T., Kim, D. W., Wu, Y. L., Nakagawa, K., Mekhail, T., . . . Investigators, P. (2014). First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med, 371(23), 2167-2177. doi:10.1056/NEJMoa1408440

Sonobe, M., Yamada, T., Sato, M., Menju, T., Aoyama, A., Sato, T., . . . Date, H. (2014). Identification of subsets of patients with favorable prognosis after recurrence in completely resected non-small cell lung cancer. Ann Surg Oncol, 21(8), 2546-2554. doi:10.1245/s10434-014-3630-9

Soria, J. C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., . . . Investigators, F. (2018). Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med, 378, 113-125. doi:10.1056/NEJMoa1713137

Soria, J. C., Tan, D. S., Chiari, R., Wu, Y. L., Paz-Ares, L., Wolf, J., . . . de Castro, G. (2017). First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet, 389(10072), 917-929. doi:10.1016/S0140-6736(17)30123-X

Spigel, D., McLeod, M., Hussein, M., Waterhouse, D., Einhorn, L., Horn, L., . . . Jotte, R. (2017). Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC). Ann Oncol, 28, v460-v496.

Spigel, D. R., Faivre-Finn, C., Gray, J. E., Vicente, D., Planchard, D., Paz-Ares, L., . . . Antonia, S. J. (2022). Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol, 40(12), 1301-1311. doi:10.1200/JCO.21.01308

Spigel, D. R., Vicente, D., Ciuleanu, T. E., Gettinger, S., Peters, S., Horn, L., . . . Reck, M. (2021). Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331. Ann Oncol, 32(5), 631-641. doi:10.1016/j.annonc.2021.01.071

Spiro, S. G. (2012). Screening for lung cancer: we still need to know more. Thorax, 67(4), 283-285. doi:10.1136/thoraxjnl-2011-201541

Stahel, R. A., Weder, W., Lievens, Y., Felip, E., & Group, E. G. W. (2010). Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21 Suppl 5, v126-128. doi:10.1093/annonc/mdq173

Stanic, S., Paulus, R., Timmerman, R. D., Michalski, J. M., Barriger, R. B., Bezjak, A., . . . Bradley, J. (2014). No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236. Int J Radiat Oncol Biol Phys, 88(5), 1092-1099. doi:10.1016/j.ijrobp.2013.12.050

Stevens, T. M., Morlote, D., Xiu, J., Swensen, J., Brandwein-Weber, M., Miettinen, M. M., . . . Bridge, J. A. (2019). NUTM1-rearranged neoplasia: a multi-institution experience yields novel fusion partners and expands the histologic spectrum. Mod Pathol, 32(6), 764-773. doi:10.1038/s41379-019-0206-z

Stovold, R., Blackhall, F., Meredith, S., Hou, J., Dive, C., & White, A. (2012). Biomarkers for small cell lung cancer: neuroendocrine, epithelial and circulating tumour cells. Lung Cancer, 76(3), 263-268. doi:10.1016/j.lungcan.2011.11.015

Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., . . . Investigators, N.-T. (2017). Phase 3 Trial of. N Engl J Med, 376(2), 125-135. doi:10.1056/NEJMoa1607427

Strøm, H. H., Bremnes, R. M., Sundstrøm, S. H., Helbekkmo, N., Fløtten, O., & Aasebø, U. (2013). Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group. Br J Cancer, 109(6), 1467-1475. doi:10.1038/bjc.2013.466

Sugarbaker, D. J., Flores, R. M., Jaklitsch, M. T., Richards, W. G., Strauss, G. M., Corson, J. M., . . . Mentzer, S. J. (1999). Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg, 117(1), 54-63.

Suh, J. H. (2010). Stereotactic radiosurgery for the management of brain metastases. N Engl J Med, 362(12), 1119-1127. doi:10.1056/NEJMct0806951

Suh, Y. J., Park, C. M., Han, K., Jeon, S. K., Kim, H., Hwang, E. J., . . . Goo, J. M. (2020). Utility of FDG PET/CT for Preoperative Staging of Non-Small Cell Lung Cancers Manifesting as Subsolid Nodules With a Solid Portion of 3 cm or Smaller. AJR Am J Roentgenol, 214(3), 514-523. doi:10.2214/ajr.19.21811

Sun, J. M., Ahn, M. J., Ahn, J. S., Um, S. W., Kim, H., Kim, H. K., . . . Park, K. (2012). Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer? Lung Cancer, 77(2), 365-370. doi:10.1016/j.lungcan.2012.04.009

Sun, L., Davis, C. W., Hwang, W. T., Jeffries, S., Sulyok, L. F., Marmarelis, M. E., . . . Aggarwal, C. (2020). Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy. Clin Lung Cancer. doi:10.1016/j.cllc.2020.10.017

Sundstrom, S., Bremnes, R., Aasebo, U., Aamdal, S., Hatlevoll, R., Brunsvig, P., . . . Kaasa, S. (2004). Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial. J Clin Oncol, 22(5), 801-810.

Sundstrom, S., Bremnes, R., Brunsvig, P., Aasebo, U., Olbjorn, K., Fayers, P. M., & Kaasa, S. (2005). Immediate or delayed radiotherapy in advanced non-small cell lung cancer (NSCLC)? Data from a prospective randomised study. Radiother Oncol, 75(2), 141-148.

Suárez-Piñera, M., Belda-Sanchis, J., Taus, A., Sánchez-Font, A., Mestre-Fusco, A., Jiménez, M., & Pijuan, L. (2018). FDG PET-CT SUVmax and IASLC/ATS/ERS histologic classification: a new profile of lung adenocarcinoma with prognostic value. Am J Nucl Med Mol Imaging, 8(2), 100-109.

Sørensen, M., Pijls-Johannesma, M., Felip, E., & Group, E. G. W. (2010). Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21 Suppl 5, v120-125. doi:10.1093/annonc/mdq172

Sørensen, S., Helweg-Larsen, S., Mouridsen, H., & Hansen, H. H. (1994). Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer, 30A(1), 22-27.

Takenaka, D., Ohno, Y., Koyama, H., Nogami, M., Onishi, Y., Matsumoto, K., . . . Sugimura, K. (2010). Integrated FDG-PET/CT vs. standard radiological examinations: comparison of capability for assessment of postoperative recurrence in non-small cell lung cancer patients. Eur J Radiol, 74(3), 458-464. doi:10.1016/j.ejrad.2009.03.007

Tapia Rico, G., Chan, M. M., & Loo, K. F. (2020). The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (Hepatitis B/C, HIV): A review of the available evidence. Cancer Treat Rev, 86, 102011. doi:10.1016/j.ctrv.2020.102011

Tassinari, D., Scarpi, E., Sartori, S., Tamburini, E., Santelmo, C., Tombesi, P., & Lazzari-Agli, L. (2009). Second-line treatments in non-small cell lung cancer. A systematic review of literature and metaanalysis of randomized clinical trials. Chest, 135(6), 1596-1609.

Tatcı, E., Özmen, Ö., Öztürk, A., & Demirağ, F. (2021). Contribution of (18)F-FDG PET/CT in the Differential Diagnosis of Pulmonary Hamartomas and Pulmonary Carcinoids. Mol Imaging Radionucl Ther, 30(2), 101-106. doi:10.4274/mirt.galenos.2021.20633

Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., . . . Lynch, T. J. (2010). Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med, 363(8), 733-742. doi:10.1056/NEJMoa1000678

Teraoka, S., Fujimoto, D., Morimoto, T., Kawachi, H., Ito, M., Sato, Y., . . . Tomii, K. (2017). Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study. J Thorac Oncol, 12(12), 1798-1805. doi:10.1016/j.jtho.2017.08.022

Thatcher, N., Nicolson, M., Groves, R. W., Steele, J., Eaby, B., Dunlop, J., . . . Ukachukwu, I. (2009). Expert consensus on the management of erlotinib-associated cutaneous toxicity in the u.k. Oncologist, 14(8), 840-847.

Travis, W. D. (2014). Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine. Thorac Surg Clin, 24(3), 257-266. doi:10.1016/j.thorsurg.2014.04.001

Travis, W. D., Brambilla, E., Rami-Porta, R., Vallières, E., Tsuboi, M., Rusch, V., . . . Committee, I. S. (2008). Visceral pleural invasion: pathologic criteria and use of elastic stains: proposal for the 7th edition of the TNM classification for lung cancer. J Thorac Oncol, 3(12), 1384-1390. doi:10.1097/JTO.0b013e31818e0d9f

Treasure, T., Lang-Lazdunski, L., Waller, D., Bliss, J. M., Tan, C., Entwisle, J., . . . trialists, M. (2011). Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol, 12(8), 763-772. doi:10.1016/S1470-2045(11)70149-8

Tsuboi, M., Herbst, R. S., John, T., Kato, T., Majem, M., Grohé, C., . . . Investigators, A. (2023). Overall Survival with Osimertinib in Resected. N Engl J Med, 389(2), 137-147. doi:10.1056/NEJMoa2304594

Tsuruoka, K., Horinouchi, H., Goto, Y., Kanda, S., Fujiwara, Y., Nokihara, H., . . . Ohe, Y. (2017). PD-L1 expression in neuroendocrine tumors of the lung. Lung Cancer, 108, 115-120. doi:10.1016/j.lungcan.2017.03.006

Turner, M. C., Andersen, Z. J., Baccarelli, A., Diver, W. R., Gapstur, S. M., Pope, C. A., . . . Cohen, A. (2020). Outdoor air pollution and cancer: An overview of the current evidence and public health recommendations. CA Cancer J Clin. doi:10.3322/caac.21632

Turrisi, A. T., Kim, K., Blum, R., Sause, W. T., Livingston, R. B., Komaki, R., . . . Johnson, D. H. (1999). Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med, 340(4), 265-271.

Upadhya, P., Ananthraju, A., Vadala, R., & Mohanty Mohapatra, M. (2021). Endocrine paraneoplastic syndromes in lung cancer: a respiratory physician's perspective. Adv Respir Med, 89(4), 403-412. doi:10.5603/ARM.a2021.0075

Vallieres, E., Shepherd, F. A., Crowley, J., Van Houtte, P., Postmus, P. E., Carney, D., . . . Goldstraw, P. (2009). The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol, 4(9), 1049-1059.

van Meerbeeck, J. P., Gaafar, R., Manegold, C., Van Klaveren, R. J., Van Marck, E. A., Vincent, M., . . . Giaccone, G. (2005). Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol, 23(28), 6881-6889.

van Meerbeeck, J. P., Kramer, G. W., Van Schil, P. E., Legrand, C., Smit, E. F., Schramel, F., . . . Group, E. O. f. R. a. T. o. C.-L. C. (2007). Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst, 99(6), 442-450. doi:10.1093/jnci/djk093

van Thiel, E. R., Surmont, V. F., & van Meerbeeck, J. P. (2011). Malignant pleural mesothelioma: when is radiation therapy indicated? Expert Rev Anticancer Ther, 11(4), 551-560. doi:10.1586/era.10.169

van Veggel, B., Madeira R Santos, J. F. V., Hashemi, S. M. S., Paats, M. S., Monkhorst, K., Heideman, D. A. M., . . . de Langen, A. J. (2020). Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer. Lung Cancer, 141, 9-13. doi:10.1016/j.lungcan.2019.12.013

Vellayappan, B., Tan, C. L., Yong, C., Khor, L. K., Koh, W. Y., Yeo, T. T., . . . Sahgal, A. (2018). Diagnosis and Management of Radiation Necrosis in Patients With Brain Metastases. Front Oncol, 8, 395. doi:10.3389/fonc.2018.00395

Vergnon, J. M., Huber, R. M., & Moghissi, K. (2006). Place of cryotherapy, brachytherapy and photodynamic therapy in therapeutic bronchoscopy of lung cancers. Eur Respir J, 28(1), 200-218.

Veronesi, G., Maisonneuve, P., Bellomi, M., Rampinelli, C., Durli, I., Bertolotti, R., & Spaggiari, L. (2012). Estimating overdiagnosis in low-dose computed tomography screening for lung cancer: a cohort study. Ann Intern Med, 157(11), 776-784. doi:10.7326/0003-4819-157-11-201212040-00005

Veronesi, G., Morandi, U., Alloisio, M., Terzi, A., Cardillo, G., Filosso, P., . . . Spaggiari, L. (2006). Large cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical cases. Lung Cancer, 53(1), 111-115. doi:10.1016/j.lungcan.2006.03.007

Veronesi, G., Novellis, P., Voulaz, E., & Alloisio, M. (2016). Robot-assisted surgery for lung cancer: State of the art and perspectives. Lung Cancer, 101, 28-34. doi:10.1016/j.lungcan.2016.09.004

Vilmann, P., Clementsen, P. F., Colella, S., Siemsen, M., De Leyn, P., Dumonceau, J. M., . . . Annema, J. T. (2015). Combined endobronchial and oesophageal endosonography for the diagnosis and staging of lung cancer. European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). Eur Respir J, 46(1), 40-60. doi:10.1183/09031936.00064515

Vogelius, I. R., & Bentzen, S. M. (2012). A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. Acta Oncol, 51(8), 975-983. doi:10.3109/0284186X.2012.718093

Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., . . . Paoletti, P. (2003). Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol, 21(14), 2636-2644.

von Meyenfeldt, E. M., Prevoo, W., Peyrot, D., Lai A Fat, N., Burgers, S. J., Wouters, M. W., & Klomp, H. M. (2011). Local progression after radiofrequency ablation for pulmonary metastases. Cancer, 117(16), 3781-3787. doi:10.1002/cncr.25958

von Pawel, J., Gatzemeier, U., Pujol, J. L., Moreau, L., Bildat, S., Ranson, M., . . . Ross, G. (2001). Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol, 19(6), 1743-1749.

von Pawel, J., Schiller, J. H., Shepherd, F. A., Fields, S. Z., Kleisbauer, J. P., Chrysson, N. G., . . . Gralla, R. (1999). Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol, 17(2), 658-667.

von Plessen, C., Bergman, B., Andresen, O., Bremnes, R. M., Sundstrom, S., Gilleryd, M., . . . Sorenson, S. (2006). Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer, 95(8), 966-973. doi:6603383 [pii] 10.1038/sj.bjc.6603383

Wahidi, M. M., Govert, J. A., Goudar, R. K., Gould, M. K., McCrory, D. C., & Physicians, A. C. o. C. (2007). Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest, 132(3 Suppl), 94S-107S. doi:10.1378/chest.07-1352

Wahl, S. G. F., Dai, H. Y., Emdal, E. F., Berg, T., Halvorsen, T. O., Ottestad, A. L., . . . Richardsen, E. (2021). The Prognostic Effect of KRAS Mutations in Non-Small Cell Lung Carcinoma Revisited: A Norwegian Multicentre Study. Cancers (Basel), 13(17). doi:10.3390/cancers13174294

Waite, K., & Gilligan, D. (2007). The role of radiotherapy in the treatment of malignant pleural mesothelioma. Clin Oncol (R Coll Radiol), 19(3), 182-187. doi:S0936-6555(06)00435-3 [pii] 10.1016/j.clon.2006.12.006

Wakelee, H., Liberman, M., Kato, T., Tsuboi, M., Lee, S. H., Gao, S., . . . Investigators, K.-. (2023). Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. N Engl J Med, 389(6), 491-503. doi:10.1056/NEJMoa2302983

Waldeland, E., Brustugun, O. T., Ramberg, C., & Helland, Å. (2012). [Stereotactic irradiation in spinal metastases]. Tidsskr Nor Laegeforen, 132(22), 2478-2479. doi:10.4045/tidsskr.12.1108

Walji, N., Chan, A. K., & Peake, D. R. (2008). Common acute oncological emergencies: diagnosis, investigation and management. Postgrad Med J, 84(994), 418-427.

Wang, E. H., Corso, C. D., Rutter, C. E., Park, H. S., Chen, A. B., Kim, A. W., . . . Yu, J. B. (2015). Postoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non-Small-Cell Lung Cancer. J Clin Oncol, 33(25), 2727-2734. doi:10.1200/JCO.2015.61.1517

Watanabe, S. M., Nekolaichuk, C. L., & Beaumont, C. (2012). The Edmonton Symptom Assessment System, a proposed tool for distress screening in cancer patients: development and refinement. Psychooncology, 21(9), 977-985. doi:10.1002/pon.1996

Weder, W., Stahel, R. A., Bernhard, J., Bodis, S., Vogt, P., Ballabeni, P., . . . Research, S. G. f. C. C. (2007). Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol, 18(7), 1196-1202. doi:10.1093/annonc/mdm093

Wei, M. L., Kang, D., Gu, L., Qiu, M., Zhengyin, L., & Mu, Y. (2013). Chemotherapy for thymic carcinoma and advanced thymoma in adults. Cochrane Database Syst Rev, 8, CD008588. doi:10.1002/14651858.CD008588.pub2

Weir-McCall, J. R., Harris, S., Miles, K. A., Qureshi, N. R., Rintoul, R. C., Dizdarevic, S., . . . Gilbert, F. J. (2021). Impact of solitary pulmonary nodule size on qualitative and quantitative assessment using 18F-fluorodeoxyglucose PET/CT: the SPUTNIK trial. Eur J Nucl Med Mol Imaging, 48(5), 1560-1569. doi:10.1007/s00259-020-05089-y

Westphalen, C. B., Krebs, M. G., Le Tourneau, C., Sokol, E. S., Maund, S. L., Wilson, T. R., . . . de Braud, F. (2021). Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population. NPJ Precis Oncol, 5(1), 69. doi:10.1038/s41698-021-00206-y

White, C. S., & Rubin, G. D. (2020). The Puzzle of the Perifissural Nodule. Radiol Cardiothorac Imaging, 2(4), e200409. doi:10.1148/ryct.2020200409

WHO Classification of Tumours 5th ed.  Thoracic tumours. (2021).  (Vol. 5). International Agency for Research on Cancer,  Lyon (France): WHO.

Wijn, D. H., Groeneveld, G. H., Vollaard, A. M., Muller, M., Wallinga, J., Gelderblom, H., & Smit, E. F. (2018). Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events. Eur J Cancer, 104, 182-187. doi:10.1016/j.ejca.2018.09.012

Wilson, J. M., & Jungner, Y. G. (1968). [Principles and practice of mass screening for disease]. Bol Oficina Sanit Panam, 65(4), 281-393.

Wilson, L. D., Detterbeck, F. C., & Yahalom, J. (2007). Clinical practice. Superior vena cava syndrome with malignant causes. N Engl J Med, 356(18), 1862-1869.

Winton, T., Livingston, R., Johnson, D., Rigas, J., Johnston, M., Butts, C., . . . Shepherd, F. (2005). Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med, 352(25), 2589-2597.

Wirth, L. J., Carter, M. R., Jänne, P. A., & Johnson, B. E. (2004). Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer, 44(2), 213-220. doi:10.1016/j.lungcan.2003.11.016

Wolf, J., Helland, Å., Oh, I. J., Migliorino, M. R., Dziadziuszko, R., Wrona, A., . . . Novello, S. (2022). Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer. ESMO Open, 7(1), 100333. doi:10.1016/j.esmoop.2021.100333

Wolf, J., Seto, T., Han, J. Y., Reguart, N., Garon, E. B., Groen, H. J. M., . . . Investigators, G. m.-. (2020). Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med, 383(10), 944-957. doi:10.1056/NEJMoa2002787

Wolfson, A. H., Bae, K., Komaki, R., Meyers, C., Movsas, B., Le Pechoux, C., . . . Choy, H. (2011). Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys, 81(1), 77-84. doi:10.1016/j.ijrobp.2010.05.013

Wolin, E. M. (2017). Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung. Chest, 151(5), 1141-1146. doi:10.1016/j.chest.2016.06.018

Wu, D., Liu, Y. Y., Wang, T., Huang, Y. Y., & Xia, P. (2023). Computed tomography-guided lung biopsy with rapid on-site evaluation for diagnosis of lung lesions: a meta-analysis. J Cardiothorac Surg, 18(1), 122. doi:10.1186/s13019-023-02212-6

Wu, J. Y., Yu, C. J., & Shih, J. Y. (2019). Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations. Clin Lung Cancer, 20(6), e620-e630. doi:10.1016/j.cllc.2019.06.018

Wu, Y. L., Ahn, M. J., Garassino, M. C., Han, J. Y., Katakami, N., Kim, H. R., . . . Mok, T. S. K. (2018). CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). J Clin Oncol, 36(26), 2702-2709. doi:10.1200/JCO.2018.77.9363

Wu, Y. L., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., . . . Mok, T. S. (2017). Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol, 18(11), 1454-1466. doi:10.1016/S1470-2045(17)30608-3

Wu, Y. L., Tsuboi, M., He, J., John, T., Grohe, C., Majem, M., . . . Investigators, A. (2020). Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med, 383(18), 1711-1723. doi:10.1056/NEJMoa2027071

Yamamoto, M., Serizawa, T., Shuto, T., Akabane, A., Higuchi, Y., Kawagishi, J., . . . Jokura, H. (2014). Stereotactic radiosurgery for patients with brain metastases - authors' reply. Lancet Oncol, 15(7), e248. doi:10.1016/S1470-2045(14)70221-9

Yang, B., Lee, H., Um, S. W., Kim, K., Zo, J. I., Shim, Y. M., . . . Kim, H. (2019). Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations. Lung Cancer, 129, 28-34. doi:10.1016/j.lungcan.2018.12.027

Yang, J. C., Schuler, M., Popat, S., Miura, S., Heeke, S., Park, K., . . . Kim, E. S. (2020). Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. J Thorac Oncol, 15(5), 803-815. doi:10.1016/j.jtho.2019.12.126

Yang, J. C., Sequist, L. V., Geater, S. L., Tsai, C. M., Mok, T. S., Schuler, M., . . . Wu, Y. L. (2015). Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol, 16(7), 830-838. doi:10.1016/S1470-2045(15)00026-1

Yang, S. Y., Kim, D. G., Lee, S. H., Chung, H. T., Paek, S. H., Hyun Kim, J., . . . Han, D. H. (2008). Pulmonary resection in patients with nonsmall-cell lung cancer treated with gamma-knife radiosurgery for synchronous brain metastases. Cancer, 112(8), 1780-1786. doi:10.1002/cncr.23357

Yao, J. C., Fazio, N., Singh, S., Buzzoni, R., Carnaghi, C., Wolin, E., . . . RAD001 in Advanced Neuroendocrine Tumours, F. u. T. R.-S. G. (2016). Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet, 387(10022), 968-977. doi:10.1016/S0140-6736(15)00817-X

Yokoba, M., Ichikawa, T., Harada, S., Naito, M., Sato, Y., & Katagiri, M. (2018). Postoperative pulmonary function changes according to the resected lobe: a 1-year follow-up study of lobectomized patients. J Thorac Dis, 10(12), 6891-6902. doi:10.21037/jtd.2018.11.108

Yu, J. B., Decker, R. H., Detterbeck, F. C., & Wilson, L. D. (2010). Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer. J Thorac Oncol, 5(2), 215-219. doi:10.1097/JTO.0b013e3181cd3208

Yuen, A. R., Zou, G., Turrisi, A. T., Sause, W., Komaki, R., Wagner, H., . . . Johnson, D. H. (2000). Similar outcome of elderly patients in intergroup trial 0096: Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer, 89(9), 1953-1960.

Zalcman, G., Mazieres, J., Margery, J., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., . . . (IFCT), F. C. T. I. (2016). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet, 387(10026), 1405-1414. doi:10.1016/S0140-6736(15)01238-6

Zeng, H., De Ruysscher, D., X, H., Zheng, D., Yang, L., Ricardi, U., . . . Hendriks, L. (2022). Radiotherapy for small cell lung cancer in current clinical practice guidelines. J Natl Cancer Cent, 2(2), 113-125.

Zhao, C., & Rajan, A. (2019). Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk? Mediastinum, 3. doi:10.21037/med.2019.08.02

Zhu, Z., Ni, J., Cai, X., Su, S., Zhuang, H., Yang, Z., . . . Fu, X. (2022). International consensus on radiotherapy in metastatic non-small cell lung cancer. Transl Lung Cancer Res, 11(9), 1763-1795. doi:10.21037/tlcr-22-644

Özgüroğlu, M., Kilickap, S., Sezer, A., Gümüş, M., Bondarenko, I., Gogishvili, M., . . . Rietschel, P. (2023). First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial. Lancet Oncol, 24(9), 989-1001. doi:10.1016/S1470-2045(23)00329-7

Siste faglige endring: 09. april 2024